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ABSTRACT 
MS is a chronic inflammatory demyelinating disease of the CNS that implies impaired motor- 
and cognitive functions. Life expectancy is not severely affected but the disease has substantial 
negative effects on the quality of life of patients and their relatives. The etiology still remains 
unknown, but both genetic as well as environmental factors are considered to contribute to 
disease susceptibility. The importance of environmental factors is supported by findings such as 
the MS latitude gradient with increasing incidence closer to the poles and from findings of twin 
studies where the healthy twin in monozygotic twin pairs discordant for disease have a less than 
30% risk for developing MS. A viral etiology was first proposed based on findings of local MS 
outbreaks. However, in recent years the focus has shifted to more common pathogens. HHV-6 
is a ubiquitous human herpesvirus that most people have been exposed to. With the cumulative 
body of evidences for an association to MS, HHV-6 is a strong etiological candidate and the 
focus of this thesis has therefore been to investigate its role in MS. 
 
The main aim of my PhD thesis was to investigate a mechanism by which HHV-6 might induce 
breakage of tolerance and subsequent autoimmune attacks against myelin, which is the primary 
target in MS, by constituting an adjuvant effect. Firstly, we present a new Q-PCR based TCID50 
read-out method for unequivocal determination of the infectivity of HHV-6 viral stocks. The 
validation revealed that the new approach is more robust compared to established methods 
(paper I). Secondly, we show that HHV-6A is not a potent adjuvant as a non-productive 
infection of HHV-6A in DC reduces IL-8 secretion and reduces the capacity of DC to stimulate 
allogenic T cell proliferation. However, HHV-6A exposure of DC leads to the up-regulation of 
HLA-ABC, via autocrine IFN-α signaling, as well as the up-regulation of HLA-DR and 
CD86, suggesting that DC get partially activated (paper II). To investigate the clinical 
relevance of HHV-6 in MS, we characterized MS plasma and CSF for viral DNA and MS 
plasma for antiviral IgG antibodies. We show no significant difference in the frequency of 
HHV-6 DNA in plasma or CSF (paper III) or in the status or levels of the antiviral IgG 
response. However, in paper IV we show that several factors previously associated with MS 
susceptibility are associated with the antiviral IgG response. Carriership of the MS protective 
allele HLA-A*02 is associated with lower antibody levels, possibly reflecting efficient 
cellular antiviral immunity in HLA-A*02 carriers. The MS risk factor smoking is associated 
with lower antibody levels, which may reflect a previously shown general decrease in IgG 
levels in smokers. Women had higher antibody levels, possibly due to a more active general 
humoral immunity, as previously shown. Finally, in paper V using GWAS SNP genotyping 
we show that carriership of the allele HLA-DQA1*05 is associated with higher antibody 
levels. Furthermore, we provide a list of 31 host genes with suggestive association to anti-
HHV-6 IgG antibody status and 29 host genes with suggestive association to antibody levels 
that contain or lies within 50 kb of the tagging SNP. The most interesting genes are KSR-2 
with suggestive associated to antibody status, and TRBV5-1, CMIP, RUNX1 and MAML3 with 
suggestive associated to antibody levels. Several of these genes have vital impact on T cell 
biology and potential importance for steering Th cells into Th1 or Th2 polarization.  
 
To conclude, the results in this thesis provide a robust read-out approach for TCID50 assays of 
HHV-6A. Furthermore, they expand our understanding for interactions between HHV-6 and 
the cellular and humoral parts of our immune system and reveal novel insights in cellular 
pathways with potential importance for anti-HHV-6 immunity. 
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1 INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
In 1838 Robert Carswell reported observations of lesions in the dissected brain of a 
deceased individual. Referring to the histopathological picture of the condition with 
several (or multiple) scars (or sclerosis) of lesions, the disease where named multiple 
sclerosis (MS). In the central nervous system (CNS) myelin sheaths surround the axons 
for insulation to enhance the speed of nerve signals. Myelin sheaths consist of densely 
packed cell membrane extensions of oligodendrocytes. In MS the myelin sheaths and 
oligodendrocytes are degraded resulting in reduced velocity of nerve signaling between 
neurons with naked axons. Clinically this can lead to impairment of all functions 
controlled by the CNS such as motor and cognitive functions, fatigue and bladder 
control etcetera (reviewed in [1]). MS onset is typically seen between 20 and 40 years 
of age. Life expectancy is not severely affected [2] but the disease has substantial 
negative effects on the quality of life of patients and their relatives [3]. The disease also 
imposes a high economical costs for society due to expensive treatments [4]. 
Worldwide, at date an estimated 2.5 million individuals are affected, and there is a 
lifetime risk of one in 400 to get the disease [1]. Furthermore, females have an 
approximately two times increased risk to develop MS compared to males [5].  
 
1.1.1 Diagnosis and pathophysiology 
To set an MS diagnosis the neurologist can use several different techniques apart from 
clinical examination but in essence CNS lesions and/or positive clinical evaluations 
must be disseminated in time and space [6, 7]. If only one clinical relapse and/or CNS 
lesion are observed the diagnosis is clinically isolated syndrome (CIS), but most 
patients with CIS subsequently convert to MS. After onset, the disease typically follows 
a relapsing-remitting course (RRMS) with periods of nearly complete recovery. But as 
the disease progresses the clinical status is aggravated and symptoms are accumulating. 
Eventually around 65% of patients with RRMS enter a progressive phase, called 
secondary progressive (SP) MS (figure 1A). In 20% of patients the disease is 
progressive from onset, called primary progressive (PP) MS. In both SPMS and PPMS 
progression starts around 40 years of age (reviewed in [8]) suggesting that the 
pathological events of the progressive phase follow the same course in both phenotypes 
but symptoms might be subclinical in initial phases of PPMS prior to diagnosis (figure 
1B). 
 
Induction of adaptive autoimmune responses such as activation and infiltration of T and 
B lymphocytes against myelin proteins in the MS brains is believed to be one important 
mechanism for the demyelination and was described already in 1868 by Jean-Martin 
Charcot (reviewed by [9]). Even though the importance of an immune component in 
MS has been questioned [10] there is a cumulative body of evidence that inflammation 
is central for the disease pathogenesis. This is given by recent advances in MS genetics 
that link several immune genes to disease incidence [11, 12] and the efficacy of 
immunomodulatory treatment for the disease. An early developed tool in the diagnosis 
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of MS is the investigations of oligoclonal IgG bands (OCB). The principal is that paired 
plasma and cerebrospinal fluid (CSF) samples from the same patient are run on gel 
electrophoresis. Distinct bands present in CSF but not in plasma are called OCBs, 
which are seen in a majority of patients, and these band constitute of antibody products 
from expanded B cell clones [13]. This suggests an accumulation of B cell clones in the 
CNS that is not seen in the periphery. The involvement of B cells is further supported 
by findings of formation of ectopic germinal centers in MS brains [14]. Even though B 
cells seem important the predominant immune cell types in MS lesions are cluster of 
differentiation (CD) 8+ T cells [15]. 
 
Before entering the CNS, immune cells need to cross the blood-brain barrier (BBB) 
that is formed by tight junctions between the endothelial cells in the capillaries 
branching into the brain, and thereby separating the CNS from the periphery [16]. 
However, T cells express the integrin receptor α4β1 (very late antigen (VLA)-4) on 
their cell surface upon activation via antigen presenting cells (APCs) can then bind 
vascular cell adhesion molecule 1 (VCAM-1) to facilitate the migration through the 
BBB. VCAM-1 is expressed on the endothelial cells of the blood vessels upon 
stimulation by inflammatory cytokines such as tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β and interferon (IFN)-γ [17]. Once inside the CNS the CD4+ T cells 
need to find their antigen in order to execute their functions. In MS lesions, cytotoxic 
CD8+ T cells are the predominant immune cell type interacting with cell surface bound 
human leucocyte antigen (HLA) class I molecules on various glial cell types and 
neurons, executing cytotoxic actions as seen by granzyme B expression. Demyelination 
is the hallmark event in MS and therefore oligodendrocytes are thought to be the main 
target, at least in the early event of disease [15]. However, based on findings from 
experimental autoimmune encephalopathy (EAE) where adoptive transfer of 
autoreactive CD4+ T cells alone induced disease, CD4+ T cells are thought to be the 
driver of disease [18]. 
 
 
Figure 1. The clinical course of MS. During initial phases of RRMS patients recover to a large extent 
during the remitting phases but as the disease progresses the clinical status is aggravated and symptoms 
are accumulating. Eventually around 65% of patients with RRMS enter a progressive phase, SPMS. In 
20% of patients the disease is progressive from onset, PPMS (A). The general consensus in the field is 
that inflammation has the primary role in the initiation of disease followed by axonal loss. The loss of 
brain tissue such as oligodendrocytes and neurons leads to a reduction of brain volume (B). Reprinted 
from The Lancet, 372(9648), Compston, A. and A. Coles, Multiple sclerosis. p. 1502-17, (2008) with 
permission from Elsevier.  
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1.1.2 Risk factors 
1.1.2.1 Genetic risk factors 
The importance of inflammation in MS was illuminated by genetic findings including 
the very first identified MS associated gene allele in the 1970s, HLA-DRB1*15 [19, 
20]. It lies within the HLA region that contains genes with crucial roles in the immune 
system. It would take another thirty years until the next gene allele was identified, 
HLA-A*02 [21], also that a gene within the HLA region. Whereas presence of HLA-
DRB1*15 increases the risk of MS around 3 times presence of HLA-A*02 reduces the 
risk by half. Interestingly, individuals homozygous for HLA-DRB1*15 and lacking 
HLA-A*02 have a 23 time increased risk for MS [22]. The introduction of genome wide 
association studies (GWAS), where hundreds of thousands of single nucleotide 
polymorphisms (SNPs) spanning the entire genome are genotyped, has led to a virtual 
explosion of newly identified MS associated genes [11, 12]. To date, the list comprises 
110 different non-HLA genes associated to MS onset. The various genotypes identified 
in GWAS studies typically have small effects on susceptibility. In combination with the 
correction for multiple testing very large materials with tens of thousands of individuals 
are included to get sufficient power in the statistical analyses.  
 
Hence, genetics seems to play a role. And indeed the unaffected twin in discordant 
monozygotic twin pairs, whose genetic code is 100% identical, have around 30% risk 
of developing disease, according to a meta-analysis of populations based surveys [8] 
(figure 2). A recent and yet unpublished population registry-based Swedish study 
suggests that this risk is even lower, under 24% (personal communication with Helga 
Westerlind). The recurrence risk decreases with decreased genetic sharing suggesting a 
dose effect of genetic sharing that furthermore supports the importance of genetics in 
MS disease. However, genetics cannot explain the remaining 70-76% of the lifetime 
risk to get MS. This suggests that environmental factors are of substantial importance, 
especially as close family members often share environment. 
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Figure 2. Recurrence risks for relatives to MS patients to get the disease. The recurrence risk increases 
with increased genetic sharing suggesting that genetics is important. But even with 100% of genetic 
sharing, as for monozygotic twins, the recurrence risk is only around 30% suggesting that also 
environmental factors are important. The data is based on population based surveys and error bars 
represents estimated 95% confidence intervals. Reprinted from The Lancet, 372(9648), Compston, A. 
and A. Coles, Multiple sclerosis. p. 1502-17, (2008) with permission from Elsevier.  
 
1.1.2.2 Environmental risk factors 
The role of various environmental risk factors in MS susceptibility is supported by a 
substantial amount of studies. One interesting phenomenon is that MS susceptibility 
increases in populations living closer to the poles on both hemispheres [23].  
Furthermore, migration from a high-risk area to a low-risk area decreases the incidence 
of MS, but only if the migration is done before the age of 15 years [24]. The general 
interpretation of these results is that environmental factors seem to be important in MS, 
and that the disease is acquired during adolescence.  
 
1.1.2.2.1 Environmental risk factors - non infectious 
The most intuitive mechanism underlying the notion of increased MS prevalence closer 
to the poles is sun exposure and ultraviolet (UV) radiation, which vary with latitude. 
UV light impact biological processes, it can destroy DNA [25] and cause skin cancer 
[26]. However UV irradiation also has positive effects such as inactivation of viruses 
[27] (applied in papers I and II of this thesis) and induction of the conversion of 7-
dehydrocholesterol in the skin to pre-vitamin D, which in turn is converted to the vital 
steroid vitamin D [28]. There is accumulating evidence that vitamin D has a central role 
in MS. Vitamin D deficiency in blood has been correlated to increase incidence of MS 
[29]. Furthermore, a vitamin D rich diet has been associated with enhanced recovery 
from EAE in rat; and a decreased incidence of MS has been seen in people living in 
coastal areas with a fish based diet compared to people living in the inland of Norway 
(reviewed in [30]), which has a high MS prevalence (0.16%) [31]. Finally, there is a 
negative relationship between sun exposure and the risk for first demyelinating events 
[32]. 
 
The cytochrome P450 (CYP) 27B gene has been associated to MS susceptibility [11, 
33, 34] and CYP27B is an enzyme that is involved in the transformation of vitamin D 
to its active form 1,25 dihydroxy vitamin D (1,25(OH)2D3) [35]. The classical roles of 
1,25(OH)2D3 are regulation of calcium and phosphate homeostasis but 1,25(OH)2D3 
has been suggested to have additional roles such as effecting differentiation and 
functions of immune cells [36]. Together the findings of vitamin D deficiency as a risk 
factor for MS, the MS protective effect of vitamin D rich diets and the genetic 
association between MS susceptibility and CYP27B provide a strong indication that 
vitamin D is important in MS.  
 
Vitamin D has multiple and complex effects on the immune system but they seem to go 
in the anti-inflammatory direction (reviewed in [37]). Differentiation of human 
monocytes to dendritic cells (DC) is inhibited as well as secretion of the pro-
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inflammatory cytokines IL-12 and IFN-γ, and in contrast secretion of the anti-
inflammatory cytokine IL-10 is enhanced upon stimulation with 1,25(OH)2D3 [38]. The 
immunosuppressive effect of 1,25(OH)2D3 seems to be even stronger in dermal APCs 
as the surface expression of co-stimulatory molecules is decreased on dermal DC and 
as the capacity of these APCs) to stimulate proliferation of allogenic naïve CD4+ T 
cells is impaired.  Furthermore, 1,25(OH)2D3 treated Langerhans cells induce skewing 
of CD4+ T cells into FoxP3 Treg phenotypes [39]. Vitamin D also seems to have direct 
effects on human T cells that follow the same path of tolerance induction, as treatment 
with a vitamin D analogue suppressed proliferation of anti-CD3 stimulated CD4+ and 
CD8+ T cells, suppressed secretion of the pro-inflammatory cytokines IFN-γ, IL-17 
and IL-4, and in contrast enhanced secretion of IL-10 and expression of cytotoxic T 
lymphocyte antigen (CTLA)-4 [40]. CTLA-4 in turn is a ligand on T cells for the co-
stimulatory molecules CD80 and CD86 on APCs that antagonizes the binding of CD28 
on T cells, which results in blockage of T cell activation signaling (reviewed in [41]). 
Given the supports for an anti-inflammatory effect, 1,25(OH)2D3 is on the other hand 
vital for signaling downstream of the T cell receptor (TCR) in humans [42]. This 
finding does not necessarily suggest a pro-inflammatory effect of vitamin D and 
together the literature seems to point in the direction of an anti-inflammatory effect for 
vitamin D in humans. 
 
As for vitamin D, an immunomodulatory activity is also a possible mechanistic 
explanation behind the increased MS susceptibility upon active [43] and passive [44] 
smoking. More specifically an increased activation of T cells by DC has been observed 
in the lungs of smokers [45]. Another explanation is given by findings of increased 
expression of matrix metalloproteinases (MMPs) on immune cells and in body fluids 
of smokers. MMPs are involved in the trafficking of immune cells over the BBB and an 
increased levels of these enzymes might facilitate the crossing of immune cells, 
including autoreactive cells [46]. As not all people who smoke develop MS, it is likely 
that the mechanisms of smoking in combination with other factors are dangerous, from 
an MS perspective. A link between smoking and infections is provided by a decrease in 
the general antibody response among smokers [47]. 
 
1.1.2.2.2 Environmental risk factors - infectious 
The role of a functional immune system is to protect us from infections, and maintain 
tolerance to self [48]. The hygiene hypothesis assumes that a high exposure of 
microbes keeps the immune system busy preventing it from attacking body tissues. 
This is supported by findings including that children growing up on farms were 
exposed to a wider range of microbes which lowered their risk of developing asthma 
[49]. The hygiene hypothesis also assumes that infections early in life are handled in 
a better way when the immune system is more active by providing an efficient 
immunological memory that optimizes the mechanisms of clearing the pathogen upon 
exposure later in life. This model has been proposed also for MS. An early Israeli 
study based on questionnaires suggested that a high hygienic standard at age 10 
imposed an increased susceptibility risk for MS later in life [50]. 
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In contrast to the hygiene hypothesis the theory that an infectious agent can trigger MS 
has been put forward. The immune system seems to be important in MS. But the 
hypothesis that inflammation is the primary event in MS is based on negative findings. 
Which is the notion that no causal link has yet been established to any pathogen, as 
Hafler et al. points out in an important review [9]. The potential of a viral cause in MS 
is suggested by an experimental animal model where infection of susceptible mice 
strains with Theiler’s virus induces immune mediated demyelination [51]. Over the 
years a long list of different infectious pathogens has been expected to be associated 
with MS [52]. The idea that MS is infectious came from experiences of several MS 
epidemics at the Faroe Islands starting in 1943 upon occupation by British troops that 
were suspected to carry an MS specific pathogen, primary multiple sclerosis affection 
(PMSA) [53]. However, a potential bias here is that among the British soldiers there 
might have been clinicians that were the first westerners to observe MS in the Faroe 
Islands. Hence, the disease might have been present before the islands were occupied, 
when the natives were not observed by westerners. 
 
Virus infections tend to fluctuate with season and are in general more frequent in 
populations of the northern hemisphere during the period around October to April [54-
56], probably primarily due to our tendency to squeeze together indoor in smaller areas 
to a larger extent than during summer. Other mechanisms might be the antiviral effect 
of UV irradiation described above [27] and also that virions maintain their structures 
better if they are sneezed out in sub-zero Celsius degree environments during winter 
compared to in warmer environments during summer. Maternal antibodies that are 
transferred over the placenta during pregnancy [57] gradually degrade and are lost at 
around six months of age [58]. If MS is caused by a common viral infection early in 
life, that the vast majority of the population has been exposed to, the handling of the 
infection is probably the critical event, and not the exposure status. If a vigorous 
primary infection is a larger risk factor compared to a milder primary infection by the 
same virus, then one could argue that it would be beneficial to encounter the first winter 
cascade of viral infections armed with maternal antibodies and spend the subsequent 
coming summer period to gradually build up an autonomous immune defense. A 
population based study by Willer et al. [59] of MS cases in the northern hemisphere 
showed that significantly more MS patients were born in May and fewer in November. 
The data were based on a large study group consisting of over 42 000 MS patients in 
total to enable detection of the small effects of more patients born in May (9.1%) and 
fewer in November (8.5%), but still the study contributes an important observation. 
Given the antiviral effect of UV irradiation, the hypothesis of a causal relationship of a 
viral infections early in life and development of MS in adulthood, is supported by a 
study where increased sun exposure during childhood was shown to be associated with 
decreased MS susceptibility [60]. 
 
The relationships between all known human herpesviruses and MS have been 
investigated. Interestingly, HHV-6 was the only virus found significantly more often in 
MS patients in a screening of MS patients and healthy controls peripheral blood 
mononuclear cells (PBMCs) for DNA of seven different human herpesviruses [61]. 
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Even though this thesis is focusing on HHV-6 in MS, Epstein-Barr virus (EBV) should 
be mentioned. In recent years an accumulating body of evidence for an association 
between EBV and MS has grown and made it a popular pathogen in MS etiology. The 
most important findings include increased [62, 63] IgG titers against the Epstein-Barr 
nuclear antigen (EBNA) 1 in serum from MS patients compared to controls and OCB 
specificity against EBV [64]. However, the mechanism of EBNA-1 in MS disease has 
not been elucidated. There seems to be some controversy on whether this increase is 
seen prior to, or following MS onset. A role for EBV in clinical relapses has been 
proposed by findings of increased anti-EBV CD8+ T cell reactivity during active 
phases of MS [65]. The role of EBV in the brain was suggested in an elegant study by 
Aloisi et al. showing infiltration of EBV transformed B cells and formation of ectopic 
germinal centers in MS brains, and these germinal centers were shown to be the 
primary site for EBV persistence [14]. Even though this finding has been questioned 
[66] it remains an important piece of the MS pathophysiological puzzle. Indeed, 
transformation of B cells by EBV is performed routinely in vitro to develop continuous 
B cell lines. If this occurs in the human body, a transformed B cell clone with B cell 
receptor (BCR) specificity against myelin proteins would potentially aggravate the 
pathogenesis. EBV infection often occurs early in life and is then asymptomatic [67]. 
Primary infection of EBV in adolescents and adults however, can cause infectious 
mononucleosis (IM) [68, 69] leading to an increased risk for MS in EBV seronegative 
persons [70], and IM increases the risk for developing MS [71, 72]. Hence, if EBV can 
cause MS disease, then EBV induced MS onset would occur during adolescence. This 
is further supported by a study of pediatric MS where a decreased status of IgG 
antibodies against the EBV proteins EBNA-1 and viral capsid antigen (VCA) was seen 
in MS cases compared to in healthy pediatric controls [73]. Given these evidences, the 
possibility that the findings of an EBV association in MS are rather consequences than 
causes of the disease cannot be ruled out. Therefore, to prove a causal relationship an 
idea is established within the field that a clinical trial should be conducted where MS 
patients are treated with anti-EBV drugs [74].  
 
1.1.3 Treatments 
Given the inflammatory component in MS the successful treatment used at date is 
focusing on dampening the activity of the immune system. Interferon (IFN )-β is a first 
line treatment for relapsing-remitting MS that reduces the relapse frequency by around 
30%  and the lesion load seen by magnetic resonance imaging (MRI), but does not 
seem to effect disease progression [75, 76]. Together with IFN-α, IFN-β constitutes the 
type I IFN family. Short term effects of type I IFN includes the induction of 
enhancement of antibody production of B cells via CD4+ T cells and the differentiation 
of CD4+ T cells into IFN-γ secreting Th1 cells, and cross-priming of antigen specific 
CD8+ T cells (reviewed in [77]). Therefore IFN-β is also an important antiviral 
cytokine [78]. Indeed, treatment with IFN-β has been shown to reduce the HHV-6A 
DNA load in serum of MS patients [79]. However, the antiviral effects are not regarded 
as the primary mode of action for IFN-β treatment. The effects of this cytokine, when 
administered continually for long periods of time, seem to differ from the acute effects. 
A subset of the chronic effects of IFN-β treatment, that seems to be responsible for the 
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dampening of the disease, include suppressive effect on the co-stimulatory molecule 
CD80 on APC [80] and the potentially reducing capacity of APC to activate T cells, its 
counteracting effect on IFN-γ signaling [81], its potential to skew the CD4+ T cell 
repertoire towards a more anti-inflammatory T helper (Th) 2 profile and its inhibitory 
effect of trans-migration of leucocytes over the BBB [82].  
 
Another first-line treatment against MS is glatiramer acetate (GA). It constitutes a 
random polymer of four amino acids found in myelin basic protein (MBP) that was 
initially intended to be used for induction of experimental autoimmune 
encephalomyelitis (EAE), but instead was fond to reduce EAE in rhesus monkeys after 
initiation and onset of symptoms of EAE [83]. A tolerance inducing effect of GA on 
DC has been suggested by findings of decreased TNF and IL-12 production, and 
increased IL-10 production by DC from GA treated MS patients, compared to untreated 
MS patients [84]. Treatment with GA is similarly effective as with IFN-β [85]. 
 
Natalizumab is a second line treatment in MS. It is a monoclonal antibody (MAb) 
specific to VLA-4 [86]. It antagonizes VLA-4 and thereby prevents the infiltration of 
lymphocytes into the brain, and also other tissues. Natalizumab is more efficient than 
IFN-β in reducing white matter lesions and relapse risk but longitudinal monitoring of 
treated patients has revealed a horrifying side effect. VLA-4 is expressed on all 
activated T cells, independently of its TCR specificity. Hence, not only myelin specific 
but also T cells specific to different viruses are prevented to enter the brain. John 
Cunningham virus (JCV) is a common virus with a seroprevalence of 44-92% in the 
normal population depending on geographical region [87], and MS patients seems to be 
exposed to a similar extent [88]. Reactivation is normally kept in check by immune 
surveillance of leucocytes roaming the tissues. In a small number of natalizumab 
treated patients (2.1 cases per 1000 treated patients in February 2012 [89]) led to 
reactivation of JCV and development of progressive multifocal leukoencephalopathy 
(PML). The prevention of immune surveillance is suggested as a causative mechanism 
due to a decrease in general serum IgG load, in addition to the the block of T cells, and 
increased reactivation of other common latent viruses such as HHV-6 [90]. 
 
Parental administration of therapeutic IFN-β and natalizumab can induce the 
development of neutralizing anti-drug antibodies (NAbs). It is an obstacle that has been 
shown to block the efficacy of both IFN-β [91] and natalizumab [92] but does not seem 
to be a major problem for GA. Given the differences between these three established 
MS treatments, a common theme is their immunomodulatory capacities. Whereas 
natalizumab, and possibly also IFN-β, prevents influx of immune cells in the CNS, the 
mode of action for GA seems to be by inducing anergy. 
 
1.2 IMMUNITY AND AUTOIMMUNITY 
1.2.1 T and B cells 
Anergy and tolerance is the counterparts of immune activation and autoimmunity 
respectively. An efficient immune system that can protect us from pathogens need the 
capacity to elicit strong responses to kill the invading pathogen before it replicate and 
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multiply beyond control. The actions of our immune system are powerful so we need 
the immune cells to be specific to target only foreign proteins to avoid reactivity against 
our own body cells and tissues. 
 
The processes of negative and positive selection during T cell development in the 
thymus prevent autoreactive T cells to enter the peripheral blood [93]. In the classical 
model the strength of the interaction between major histocompatibility complex (MHC) 
molecules with bound self-peptide, and the TCR determines the faith of the T cell. If 
the interaction is too weak the T cell dies by neglect, and if the interaction is too strong 
the T cell dies via induction of activation [94]. Intermediate interaction, on the other 
hand, saves the T cell from apoptosis. A classification of two different T cell lineages is 
defined by the constitution of their TCR. One lineage is called αβ T cells, simply as 
their TCR are constituted by the alpha (α) chain together with the beta (β) chain, and αβ 
T cells constitute the vast majority of T cells in the circulation. Another lineage is 
called γδ T cells as the gamma (γ) and delta (δ) chains constitute their TCR. They are 
less common in the circulation and are mainly located at sites in the body that are 
exposed to the exterior, such as in the epithelia of the gut and the skin (reviewed in 
[95]). The αβTCR domain on αβ T cells can bind MHC molecules on different cell 
types during different stages of T cell development and immune responses. During 
development the αβTCR complex binds to MHC molecules on thymic epithelial and 
thymic APCs, and during activation to MHC molecules on peripheral APCs. During 
execution of effector functions, the αβTCR variable chain complex on CD4+ T helper 
cells bind to MHC class II molecules on B cells, and on cytotoxic CD8+ T cells to 
MHC class I molecules on target cells such as virus infected cells (reviewed in [96]). B 
cells develop in the bone marrow but before they enter the circulation they also undergo 
selection processes. B cells that bind to self-antigens with their BCR are either cleared 
via apoptosis or subjected to rearrangement of the variable regions of their BCR 
(reviewed in [97]). 
 
Despite the sophisticated control mechanism in T and B cell development, autoreactive 
T and B cells can be found in the circulation of healthy individuals [98-100]. But why 
does the immune system of some people fail to keep these autoreactive cells in check 
potentially inducing the development of autoimmune disease? For MS this is yet 
unknown. A popular mechanism for immune control is found in the Tregs. They are 
defined by their expression of the protein forkhead box P3 (FoxP3) and can be further 
subcategorized into CD4+, CD8+ and natural killer (NK) cells. Their function to 
actively suppress other lymphocytes is suggested by findings of autoimmune disease 
development in animals with FoxP3 gene deletion or FoxP3 cell depletion (reviewed in 
[101]). 
 
1.2.2 Dendritic cells 
T and B cells might mediate immune reactions but they are under control of DC. DC 
are a heterogeneous family of cells with specialized antigen presenting capacities 
(reviewed in [102]). They can engulf extracellular compounds such as virions which 
are subsequently degraded in lysosomes. Proteins of the virus ‘lysate’ are then cut and 
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degraded into peptides by the proteasome and transported to HLA molecules in the 
endoplasmic reticulum (ER). For HLA class I restricted peptides this transport typically 
occurs via the transporter associated with antigen processing (TAP) complex. The 
peptide containing HLA molecule can interact with the TCR on the T cell surface. In 
general, HLA class I molecules present short peptides [~9 aminoacids (a.a.)] from 
endogenously produced proteins and HLA class II molecule present long peptides (10-
30 a.a.) from external proteins. DC respond to microbial stimuli, such as pathogen-
associated molecular patterns (PAMPs) that are bound by pattern recognition receptors 
(PRRs) such as toll like receptors (TLR) (reviewed in [103]). In addition, DC respond 
by inflammatory stimuli, such as inflammatory cytokines. Microbial and inflammatory 
stimuli can initiate a process of cellular activation in DC termed maturation. The 
process of maturation is associated with increased surface levels of HLA and co-
stimulatory molecules, as well as enhanced production of soluble inflammatory 
mediators such as type I IFN, interleukin (IL)-8, IL-6, tumor necrosis factor (TNF) and 
IL-12 (reviewed in [104]). 
 
In the orchestration of T cells, DC interact with the TCR on the T cell using its HLA 
molecules, typically with a bound non-self peptide. The CD4 or CD8 molecules 
stabilize the interaction to HLA class I and II molecules respectively. Co-stimulatory 
molecules CD80, CD83, CD86 and CD40 on the DC bind their ligands CD28 and 
CD40L on the T cell to further strengthen the interaction (figure 3). Now the DC and T 
cell have formed a so called ‘immunological synapse’ and signals will be transmitted to 
the T cell [105]. Together with B cells and macrophages, DC constitute the group of 
APCs. They have a special ability to activate CD4+ T cells, via HLA class II 
molecules, and also CD8+ T cells, via HLA class I molecules, in a process called cross-
presentation. Viruses often hijack the replication machinery of the host cell. Hence, the 
virus infected cell display viral peptides on its HLA class I molecules to allow 
interaction with CD8+ T cells that induce apoptosis of the infected cells and thereby 
preventing the virus, such as HHV-6 to spread to neighboring cells. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. An ‘immunological synapse’ between a DC and a T cell. Reprinted from Huppa, J.B. and 
M.M. Davis, T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol, 2003. 3(12): 
p. 973-83 with permission from the Nature Publishing Group. 
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1.3 HUMAN HERPESVIRUS 6 
HHV-6 was first isolated in the mid 80’s from patients with lymphoproliferative 
disorders and acquired immunodeficiency syndrome (AIDS) [106-108] and belongs to 
the β-herpesvirus subfamily of Herpesviridae, as defined by the Baltimore 
classification system of viruses. As the other human β-herpesviruses, 
cytomegalovirus (CMV) and human herpesvirus 7 (HHV-7), HHV-6 can also 
establish lifelong latent infection in the host. HHV-6 isolates are classified into two 
distinct virus species, HHV-6A and 6B [109]. The two viruses share 90% of their 
nucleotide sequence [110]. In this thesis, HHV-6 is used when no such discrimination 
has been made. Its genome consists of an approximately 160 kilo base pairs (kbp) 
(159 321 bp for HHV-6A [111] and 162 114 bp for HHV-6B [110]) double stranded 
DNA containing 97 genes. The viral DNA is surrounded by a core, which in turn is 
enclosed by an icosahedral capsid. Finally, a lipid bilayer constitutes the outermost 
barrier to the exterior. This bilayer is from a host cell compartment and is acquired 
during viral replication and budding from the infected cell. 
 
1.3.1 Epidemiology 
At the age of two to three years, most individuals have been exposed to either HHV-
6A or HHV-6B. This is supported by an observation of HHV-6 DNA presence in 77 
cumulative percent in saliva from children sampled weekly during the first 24 months 
of life [112] and by the detection of anti-HHV-6 IgG antibodies in 100% of children 
tested at the age of 16-21 months [113]. As expected, the antibody prevalence 
decreased during the first five months of age but gradually increased and at 16 
months of age 70-100% were positive [114]. The decline in anti-HHV-6 IgG antibody 
titers was reversibly followed by an increasing frequency of children with positive 
polymerase chain reactions (PCR) for HHV-6 DNA reaching a 70% plateau at 10-12 
months of age (figure 4) [115]. Others have found this plateau at three years of age 
with a seroprevalence of over 90% and a gradual decline after 40 years of age [116], 
possibly reflecting a decreased activity of the aging immune system [117]. 
 
 
 
 
Figure 4. Anti-HHV-6 IgG antibody titers 
decline during the first four months of age 
and is reversibly followed by an increased 
frequency of children with HHV-6 DNA 
positive PCRs in PBMC. 2427 children 
were tested without acute illness. Reprinted 
with permission from Hall, C.B., et al. N 
Engl J Med, 1994. 331(7): p. 432-8. 
Copyright Massachusetts Medical Society. 
 
 
Whereas HHV-6B seems to be the predominant variant in Europe, Japan and USA 
[118-120], HHV-6A infection account for the vast majority of active HHV-6 infections 
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in sub-Saharan Africa [121]. Epidemiological reports on HHV-6 from the African 
continent are limited, but a study from West Africa report a similarly high 
seroprevalence as in other populations studied [122]. If the results from West Africa 
can be extrapolated to sub-Saharan Africa HHV-6A infection in sub-Saharan Africa 
may be as common as HHV-6B infection in the western world. To wildly speculate, 
one mechanism behind this misallocated distribution might lie in different capabilities 
of the viruses to escape immune responses. Whereas HHV-6B is able to evade type I 
IFN mediated immune defenses by shutting down the production of both IFN-α and -β 
HHV-6A does not have that same capacity [123]. Upon hepatitis C infection African 
Americans, with a more recent African heritage than Caucasians, are more resistant to 
IFN-α therapy than are Caucasians [124]. This has been suggested to be linked to a 
SNP in the IL-28B (IFN-λ3) gene [125]. Interferon-α and -λ3 both signal via the Janus 
kinase (JAK) – signal transducers and activators of transcription (STAT) pathway but 
they utilizes different cell surface receptors [126, 127] and data from a recent study 
suggest that IFN-λ signaling can compensate for a reduced responsiveness to IFN-α 
[128]. Therefore, HHV-6A might have a better chance to establish infection in 
populations of sub-Saharan Africa than in the other populations mentioned above. The 
predominance of HHV-6B in western countries and Japan is harder to interpret. One 
possibility is that replication by HHV-6A is more efficient than that of HHV-6B, and 
when type I IFN is not present HHV-6A takes over the scene. Another possibility is the 
analogy to the type I IFN story; that HHV-6A has an immune evasion strategy, such as 
suppressing secretion of a certain cytokine, that HHV-6B lacks and that this specific 
compartment of the immune response is more important for African populations than 
for Caucasians. 
 
1.3.2 Basic biology 
1.3.2.1 Transmission 
A major route of transmission for HHV-6 is via the saliva where it is shed [116] but 
congenital transmission is also important and occurs in 1% of births [129]. This can be 
acquired by transmission of chromosomally integrated (ci) HHV-6 in the germline 
[130] and also by reactivation from ciHHV-6 positive mothers to their ciHHV-6 
negative children via the placenta [131]. A route of transmission to the CNS has been 
identified in the olfactory tract [132]. 
 
1.3.2.2 Tropism 
A cellular receptor for both HHV-6A and HHV-6B is CD46 [133], a complement 
inhibitory molecule that is expressed on all nucleated cells [134]. Therefore, the viruses 
may have tropism for many different cell types, including immune cells. A 
predominant tropism is seen for CD4+ T cells [135, 136], but also CD8+ T cells [137, 
138], NK cells [139], monocytes [140, 141], macrophages [140], and DC [142-146]. 
Moreover, HHV-6 also has neurotropism and can infect neurons [147] and glial cells 
[107], including astrocytes [148], oligodendrocytes [149, 150], and microglia [150]. 
The tropism differs slightly between HHV-6A and 6B. CD134 was recently identified 
as a cellular receptor exclusive for HHV-6B [151]. A specific characteristic of the 
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dissemination of HHV-6A but not of HHV-6B includes its ability to induce cell-to-cell 
fusion via CD46 independent of virus replication. This was observed in Chinese 
hamster ovary (CHO) when they expressed human CD46, and CHO cells are normally 
highly resistant to HHV-6 infection, [152]. HHV-6A seems to be more neurotropic than 
HHV-6B. In vivo this is seen by a higher frequency of HHV-6A DNA in CSF than in 
PBMC in children, HHV-6B display the opposite pattern [153]. In vitro this is 
supported by the capacity of HHV-6A but not 6B to induce apoptosis in neurons, 
astrocytes and oligodendrocytes [154]. An increased tropism for human 
oligodendrocyte (M03.13), human astrocytoma (U373 MG), and human neuroblastoma 
(SK-N-SH) cell lines [155], and also progenitor derived astrocytes [156, 157], has also 
been observed for HHV-6A. 
 
1.3.2.3 Latency 
Given the ubiquitous nature of HHV-6 [112] and the frequent findings of reactivation 
in immunosuppressed individuals such as bone marrow transplant recipient patients 
[158, 159] most people that have ever been exposed to the virus are likely to be latently 
infected. Current data suggests that sites of latency from which HHV-6B can be 
reactivated are hematopoietic stem cells (reviewed in [160]). For HHV-6A the site of 
latency from which it can reactivate has not yet been determined but is has been 
found to persist in the CSF of children after the decline of a primary infection [161] 
suggesting the CNS as a possible site. Human herpesviruses normally achieve latency 
by covalently closed circular episomes [162-164]. It is possible that this also occurs 
during HHV-6 latency but it remains to be further investigated (reviewed in [165]). 
However, it is known that the HHV-6 genome is able to integrate its genome in the 
telomeric regions of host cell chromosomes [166], termed ciHHV-6. It occurs in 0.2-
2% of the population in UK, USA and Japan (reviewed in [167]). HHV-6A has been 
shown to be able to reactivate in vitro [168] and both HHV-6A and HHV-6B in vivo 
[131] from this chromosomally integrated state. This capacity is unique among 
human herpesviruses. 
 
1.3.2.4 Interactions with the immune system 
Another outstanding capacity of HHV-6 is its ability to spread in nearly the entire 
human population. This is probably, at least to some extent, achieved by the mild 
clinical phenotype of HHV-6 infection. A virus that immediately kills its host will have 
difficulties to spread, but a less aggressive virus inducing mild or even subclinical 
symptoms probably spread more efficiently from one, relatively healthy and mobile 
individual to another. Other beneficial characteristics of HHV-6 include its capacity to 
modulate the immune response. T cell proliferation is inhibited by HHV-6 infection by 
mechanism such as cell cycle arrest in the G2/M phase and induction of the anti-
inflammatory cytokine IL-10 [169, 170]. Suppression of IL-2 transcription and 
translation are other mechanisms that might explain the anti-proliferative effect of 
HHV-6A [171], as well as the suggested suppressive effect of both HHV-6A and HHV-
6B on LPS and IFN-γ mediated IL-12 secretion by macrophages and DC [172, 173]. 
However, the findings on IL-12 secretion are controversial as we and others have not 
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seen this effect in DC [174, 175]. This is discussed in the results and discussion section 
of paper II. Ligation of certain domains of CD46 has been shown to suppress T cell 
proliferation [176]. CD46 is a cellular receptor for HHV-6 and therefore it is possible 
that ligation of HHV-6 to CD46 has a role in the suppression of T cell proliferation 
upon HHV-6 infection. However, it remains to be investigated if HHV-6 utilizes the 
domains associated with suppressed T cell proliferation or other domains that is not 
associated with this effect.  
 
1.3.3 HHV-6 diagnostics 
When attempting to determine the prevalence and/or titer of a certain virus infection in 
a population or in vitro experimental models it is crucial to carefully choose the 
methods for sampling and laboratory analyses. This will be discussed in this section. 
 
1.3.3.1 Active infection 
The ultimate proof of an active infection with a certain virus is to isolate the virus. This 
is done by inoculating uninfected and susceptible cells (if available for the specific 
virus) in vitro by a biological sample, such as plasma, from the individual to be tested. 
A positive result is if the uninfected cells shows signs of infection such as syncytia 
formation or lysis, or signs of supported viral replication such as translation of viral 
proteins or transcription of viral messenger ribonucleic acid (mRNA). However, HHV-
6 virus isolation is a very challenging and time-demanding process. Alternative 
approaches include screening of plasma samples for cell free HHV-6 DNA by nested 
PCR. Plasma rather than PBMCs should be used [177] as HHV-6 can go into latency, 
possibly in blood cells. As most people are likely to be latently infected a positive PCR 
signal from PBMCs might be a reflection of a latent rather than an active infection. One 
problem with screening of plasma for viral DNA with PCR is that the results are only 
qualitative. A positive signal might be picked up from lysed PBMC leaking viral DNA 
[178], and not necessarily from free virions. This is further supported by a comparison 
where virus culture could be established in only 84% of samples containing HHV-6 
DNA [179].  
 
Reverse transcription (RT) PCR of HHV-6 mRNAs from PBMCs transcribed at late 
stages of viral replication and coding for structural proteins crucial for the formation 
of virions might be a more specific and strict approach, as transcripts of the late genes 
U31 and U39 were found in 91-96% of PBMC samples from children in acute stages 
of exanthem subitum where the virus had been isolated, and in no sample from 
children in the convalescent phase [180]. A third possibility when targeting viral 
DNA is real time quantitative PCR (Q-PCR) on plasma samples. This method gives a 
quantitative measure on the amount of HHV-6 DNA present and Q-PCR has been 
suggested to enable discrimination between ciHHV-6 and active infection. In 
individuals with ciHHV-6 every cell in the body contains viral DNA [165] and hence 
the viral DNA loads are typically high, between 3.5 and 5 log10 copies per milliliter 
(copies/ml) plasma. However, these levels overlap completely with the levels in 
children with acute infection where the DNA loads range between 3 and 6 log10 
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copies/ml plasma or serum [177]. Therefore, Q-PCR should be performed on PBMC 
samples as well. Whereas people with ciHHV-6 would have around 1 viral genome 
copy per leukocyte, people without ciHHV-6 experiencing a primary infection or a 
reactivation would have substantially lower viral DNA loads in their PBMC. Since 
the viral genome is incorporated in every cell in the body, there is a 50% chance that 
ciHHV-6 is inherited from parent to offspring (reviewed in [167]). So, how do you 
assess primary infection in individuals with ciHHV-6? At date the method of choice 
seems to be sequencing of HHV-6 PCR products of variable regions in the viral 
genome such as glycoprotein B [181] from samples of plasma and of purified PBMC 
from the very same individual. If the sequences are identical there’s probably leakage 
of ciHHV-6 but if they are not identical a primary infection might be at play. This 
was performed by Gravel et al. [131] when showing that transplacentally acquired 
HHV-6 from mothers with ciHHV-6 to their ciHHV-6 negative children can originate 
from the transmission of reactivated ciHHV-6. 
 
In adults active HHV-6 infection is highly transient and cell free viral DNA is rarely 
detectable [182]. Possibly because HHV-6 spread largely via cell-to-cell contact [146, 
183], instead of releasing large amounts of virions which is the case for many other 
viruses. Therefore, other strategies can be used where immunological responses to the 
virus, which are more long lasting, are measured instead. Secretion of antiviral 
immunoglobulin (Ig) M antibodies by B cells is an early event in an antiviral immune 
response. In primary infection and reactivation of HHV-6 IgM antibodies were detected 
five to seven days after onset of exanthema subitum and lasted for up to two months 
[184]. Compared to HHV-6 DNAemia, which seems to last for only a couple of days, 
this is a large time window. Detection of IgM by immunofluorescence assay (IFA) or 
enzyme-linked immunosorbent assay (ELISA) may consequently be regarded as 
indications of recent primary infection, or more rarely reactivation as IgG antibodies 
with higher affinity are normally present in these cases. The biological role of IgM 
antibodies includes the ability to bind foreign antigens or pathogens that the body has 
never been exposed to [185]. Later in the humoral immune response a shift in the 
antibody repertoire occurs [186] with affinity maturation via somatic hypermutation of 
the variable chain coding DNA and isotype switching in germinal centers, resulting in 
secretion of high affinity IgG, IgA and IgE antibodies. One problem with measuring 
IgM antibodies is that IgM production requires a relatively strong inflammatory 
response and is not always detectable upon HHV-6 reactivation [187]. In summary, in 
assessment of active HHV-6 infection various PCR techniques can be utilized for 
detection of viral DNA or mRNAs, or serological techniques measuring IgM 
antibodies. 
 
1.3.3.2 History of infection 
Given the various difficulties to detect active infection with HHV-6 described above, 
alternative strategies might be applied such as investigating the infection history. Virus 
specific IgG antibodies play important roles in antiviral immunity. Their binding to 
virions results in neutralization where the antibodies constitute a steric hindrance 
preventing the attachment of virions to permissive host cells. Another result of the 
 22 
binding is that the virions are opsonized to enhance that they are engulfed by 
phagocytosing immune cells such as macrophages.  
 
Children seroconvert upon primary HHV-6 exposure [115] and as the vast majority of 
the population over the age of two years has been exposed to the virus discrete data on 
seroprevalence is not very informative. Instead, assessing the titers of antiviral 
antibodies might give a hint on how strong a primary infection has been; or how 
strongly and/or frequently the virus has reactivated. This is done for infection with 
Varicella-Zoster virus (VZV) where the antiviral IgG titers increase during the 
convalescent phase [188]. Another example is EBV where symptomatic reactivation is 
associated with higher titers of anti-VCA IgG [189]. In vaccinology repeated 
inoculations of the vaccine are performed to boost the immune response by increased 
plasma cell counts and antibody titers. An analogy to this concept is found in the MS 
field where NAbs against therapeutic IFN-β develop in a subset of MS patients, and 
these NAbs have been shown to persist in RRMS patients after discontinued treatment, 
especially if the titers are high [190]. This suggests that repeated exposure to the 
antigen (virus, vaccine or protein) may increase the IgG antibody titers. Therefore, the 
antiviral IgG titer might reflect the number and/or magnitude of reactivations of the 
virus in a certain individual, and serve as an indication of HHV-6 infection history. An 
important aspect though is that serum anti-HHV-6 IgG titers should be considered as an 
indication of reactivations or primary infections in the past, and not as an adequate 
marker for active infection. Indeed, several studies have failed to correlate IgG 
prevalence and titers with active infection as measured with cell-free HHV-6 DNA 
[191, 192] or virus isolation [118, 193]. 
 
1.3.3.3 Titration methods 
If the presence and titers of antiviral IgG antibodies is a sign of history of infection and 
the detection of virus DNA is a direct measure of active infection and one step closer 
the actual virus neither of them answers the question on the amount of infectious 
virions in a blood sample or in an virus infected cell culture. The classical 50% tissue 
culture infectivity dose (TCID50) developed in 1938 by Reed and Muench [194] still 
holds. This method is applied for many different viruses. For the read-out of HHV-6 
infection there are different approaches available. The established read-out methods 
includes ocular inspection for cytopathic effect (CPE), i.e. enlargement of the infected 
cells [135], and IFA where the inoculated cells are stained with an antibody against a 
viral protein and inspected in a fluorescence microscope [195]. IFA is also used for 
calculation of the infectious units, i.e. the fraction of infected cells [196]. The CPE 
approach is problematic as some HHV-6 susceptible cells can enlarge even when not 
infected. 
 
1.3.4 HHV-6 in multiple sclerosis 
Whereas HHV-6B is the causative agent of exanthema subitum in young children 
[197], no disease has been clearly linked to HHV-6A. However, associations between 
HHV-6, and HHV-6A infection more specifically, and MS have been suggested by 
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numerous reports. A selection of these include findings of increased prevalence of 
HHV-6 DNA [198] and protein expression [147, 199] in MS plaques compared to in 
normal appearing white matter. A role for HHV-6 in the brain is further supported by 
increased frequencies and titers of anti-HHV-6 IgG [200, 201] and IgM [202] 
antibodies in CSF of MS patients compared to controls; and OCB specificity against 
HHV-6 [64, 203]. Intrathecal anti-HHV-6 IgG antibodies were detected in around 
20% of MS patients [203]. In the periphery HHV-6 mRNA and DNA have been found 
more frequently in PBMC and serum, respectively, in MS patients than in controls 
[204]; and a significantly increased frequency of MS patients with active HHV-6 
infection were in relapse than in remission [182, 205, 206]. Serum IgM antibodies are 
detectable in the early events of an infection and an increased frequency of anti-
HHV-6 IgM antibodies have been detected in early stages of MS [191, 207] 
indicating a role for HHV-6 in disease onset and periods of active MS disease. An 
increased frequency and titers of serum IgG antibodies against the viral latency 
associated protein U94 has also been detected [208]. This is consistent with 
association studies of MS and EBV where a slight increase in IgG titers against the 
latency associated protein EBNA-1 is frequently seen [209-211]. Furthermore, 
increased titers of serum IgG antibodies against HHV-6 were shown to positively 
associate with relapse risk in RRMS [212]. This association was seen after correction 
for IgG titers against the EBV proteins EBNA-1 and VCA. It is tempting to conclude 
that this supports the notion of an increased frequency of HHV-6 reactivation as a 
mechanism of disease activity. However, it cannot be ruled out that this rather reflect a 
locally increased immune activity in the CNS, which triggers viral reactivation, given 
that the CNS is a site of latency for HHV-6. 
 
In an experimental animal study marmosets were challenged intravenously (i.v.) and 
HHV-6A but not with HHV-6B gave clinical MS like symptoms and lesions seen by 
MRI [213]. Additional studies support the notion that HHV-6A is more central in 
MS. Firstly, HHV-6A seems to be more neurotropic, and moreover, an increased 
cellular immune response against HHV-6A, but not HHV-6B, has been reported in 
MS patients compared to healthy controls [214]. In the marmoset study the animals to 
be exposed to HHV-6A where divided into two groups based on infection route, i.v. 
or intranasal (i.n.). Whereas the i.v. challenged animals exhibited clinical symptoms 
and development an antibody response the i.n. challenged animals did not. This 
suggested that the underlying pathogenesis may lie in the immune response rather 
than the primary infection itself. A more prominent role for HHV-6A in MS is further 
supported by data from another animal model where glial cells from transgenic mice 
expressing human CD46 supported HHV-6A but not HHV-6B replication. Upon in 
vivo infection HHV-6A DNA could be detected in the brains of these mice for up to 9 
months (Reynaud et al., 8th International Conference on HHV-6&7, April 2013). In 
humans a predominant role for HHV-6A in MS is supported by the increased in vivo 
and in vitro neurotropism, an increased seroreactivity to HHV-6A compared to HHV-
6B infected cells [201] and increased detection of HHV-6A DNA in MS serum and 
CSF compared to HHV-6B [215]. 
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Even though a majority of the studies show a positive association between HHV-6 
and MS there are a number of conflicting reports where no association could be 
shown. An obstacle when reviewing the literature on HHV-6 in MS is the broad 
variety in the techniques used. A careful meta-analysis on the literature published 
between the years 1966 and 2009 was performed assessing the quality of the studies 
and their results [216]. Here, 60% of studies that were top ranked regarding study 
design, according a set of pre-determined criteria [217], showed significant 
differences between MS patients and controls. To conclude, in MS HHV-6 seems to 
be important in early stages of the disease and to have a direct effect on the CNS. 
Furthermore HHV-6A seems to have a more prominent role than HHV-6B. Even 
though most studies show a positive association the concept is still highly 
controversial and additional and carefully performed studies are urgently needed. 
 
1.3.4.1 Clinical trial 
As for the EBV field, the idea that a clinical trial where one could observe a clinical 
improvement in patients with neuroinflammatory disease after antiviral treatment 
targeting HHV-6 would be a proof of principle is strong in the HHV-6 field as well. 
This approach was actually taken in 2005 where MS patients were treated with 
valaciclovir for two years [218]. Trends were seen in patients with severe MS 
(expanded disability status scale (EDSS) >4) for treatment effects on clinical 
measures such as time to first relapse after trial onset but the differences to the 
placebo group was not statistically significant and not supported by MRI measures. 
No effects were seen for patients with mild MS (EDSS ≤4). For the virological 
outcome anti-HHV-6 IgM antibodies were measured and no effect was seen in any of 
the groups tested. Valaciclovir is a prodrug for aciclovir that is taken orally and an in 
vitro efficacy against HHV-6 had been shown a few years prior to the trial [219]. 
Furthermore it had been shown to access the CNS at concentrations of up to 22% of 
the plasma level [220]. Given the indications of a direct role for HHV-6 in the CNS 
this is an important feature. The choice of drug seemed vice until it a few months 
later was shown that it had no in vivo effect on HHV-6 [221]. Therefore, a first step in 
another attempt of this approach again would be to choose a drug with approved in 
vivo efficacy. 
 
Chronic fatigue syndrome (CFS) is another condition where the patient is suffering of 
excessive enervation and display activation of the immune system. Some studies 
suggests an association between CFS and HHV-6, but as for HHV-6 and MS, the 
hypothesis is controversial as other studies show conflicting data [222, 223]. 
Ganciclovir is a drug originally developed against CMV that also has well documented 
in vitro and in vivo efficacy against HHV-6 [224]. Valganciclovir (VGCV) is an oral 
prodrug for ganciclovir [225] that showed promising result in a small study where CFS 
patients positive for IgG against EBV and HHV-6 were treated [226]. They improved 
clinically and also showed decreased IgG titers against both viruses. This suggested 
that HHV-6 is important in CFS and that anti-HHV-6 IgG antibodies are a good 
measure of viral outcome but a more controlled study was needed to convince people 
(7
th
 International conference on HHV-6 & 7). In a subsequent randomized clinical trial 
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by the same research group [227] CFS patients were treated again with VGCV. 
Statistically significant beneficial effects on clinical measures in a subset of patients 
were observed but no decrease in IgG antibodies against neither HHV-6 nor EBV could 
be detected. This example underlines the importance of using adequate virological 
measures to identify the treatment effect on the virus. Because, even though the patients 
did improve clinically, the annoying fact that the anti-HHV-6 IgG titers did not drop 
are in favor for the idea against a HHV-6-causation. Off course one could argue that if 
a treatment improves the clinical condition it warrants further use regardless of if the 
mechanisms behind are known, as for treatments with IFN-β and GA in MS. But if the 
ultimate aim, in the effort to link HHV-6 with a disease such as CFS or MS, is to 
establish anti-HHV-6 treatment as a first line intervention in the clinic or even 
vaccination of healthy individuals, distinct virological measures are vital. Hence, if 
HHV-6 were to be proven to cause MS, what mechanisms might underlie the initial 
events? 
 
1.3.4.2 Hypothesized mechanisms for HHV-6 induced autoimmunity 
As discussed in section 1.2.2 DC are the primary conductor of T cells. DC mature upon 
exposure of PAMPs and thereafter can activate T cells. As PAMPs are not present in 
self-tissue it seems likely that they should have to be present in breakage of tolerance 
and autoimmunity. This was suggested by Polly Matzinger who proposed a model 
where APCs need a danger signal in combination with an antigen to elicit an immune 
response [228]. An example of this idea in practice is given by the animal model for 
MS, EAE. It has striking similarities with MS with infiltration of lymphocytes in the 
CNS and demyelination [229]. An important difference is however, that whereas the 
MS etiology is unknown the onset of EAE can be controlled. Typically myelin 
proteins are injected together with adjuvants to trigger autoimmune responses against 
myelin proteins. The task of the myelin proteins is to provide a myelin specific 
response. However, as exemplified by the GA treatment administration of the self-
antigen alone is not sufficient to induce breakage of tolerance. Therefore the task of the 
adjuvant is to provide the immune system with a danger signal to triggering an 
immune response. Thus, if EAE is an adequate model of MS, these two components, 
specificity and danger signals have to be included in a model of MS etiology.  
 
1.3.4.2.1 Molecular mimicry 
The two criteria danger signal and specificity are fulfilled in the molecular mimicry 
hypothesis. This hypothesis propose that this might be elicited with infection with a 
pathogen that have a peptide that can bind to the HLA molecule in a way that makes 
the peptide-HLA complex structurally similar at the site for TCR binding compared to 
myelin peptide binding [9]. Support for this model is given by findings of a seven-mere 
peptide from the HHV-6 protein U24 (residues 4-10) that is identical to a peptide in the 
myelin basic protein (MBP) (residues 96-102). These peptides were extended by the 
flanking three residues in each direction and the MBP peptide were used to expand 
MBP specific T cells. When the HHV-6 U24 peptide were used to re-stimulate these 
cells they were further expanded suggesting that the viral and MBP peptides can cross 
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react [230]. Molecular mimicry has been seen also between MBP and EBV in MS 
[231].  
 
1.3.4.2.2 Host cell protein incorporation 
We have had another working hypothesis on HHV-6 induced autoimmunity based on 
findings that HHV-6 can include host cell proteins such as CD46 and p53 in its virion 
[232, 233]. This seems to be a common phenomenon for enveloped viruses and has 
been shown for sever other viruses such as HTLV-1, Vaccinia Virus, and HIV-1 [234-
238]. Several proteins involved in immune regulation are known to be incorporated into 
the HIV virion and the virus can in itself thereby acquire antigen presenting and 
activating functions, which benefits the virus with increasing replication efficacy [239]. 
An enveloped virus (Vesicular stomatitis virus, VSV) has been suggested to selectively 
incorporate host cell surface proteins into budding virions [240] and furthermore to be 
an highly efficient trigger of autoreactive T cells from patients with postinfectious 
encephalomyelitis syndrome, when grown in myelin protein-expressing cell cultures 
[241]. This mechanism of virus-induced autoimmunity has also been suggested to 
occur in graft versus host disease, where the enveloped virus CMV incorporates a host 
cell protein (CD13) during replication, leading to the induction of autoimmunity against 
this protein [242, 243]. For MS, such a mechanism requires a virus that replicates in the 
myelin-producing oligodendrocytes. 
 
The candidate virus was found in HHV-6 since it, as described above, can infect 
oligodendrocytes and since it can establish latent infections with reactivations that 
coincide with the relapsing-remitting pattern seen in most MS patients. Furthermore, a 
number of studies suggest an association between HHV-6 and MS. Thus, our working 
hypothesis has been that breakage of tolerance and MS onset is induced when: Firstly, 
HHV-6 replicates in oligodendrocytes and incorporate myelin proteins into its virion. 
Secondly, an APC in the periphery engulf the myelin protein containing virion and is 
activated via ligation of viral motifs to PAMPs and TLRs. Thirdly, that anti-myelin 
specific T cells can be activated by these APCs as the engulfed HHV-6 virion carried 
myelin proteins. Lastly, these activated myelin specific T cells can enter the brain and, 
if they express CD8, destroy oligodendrocytes or, if the express CD4, constitute help to 
B cells which start to produce anti-myelin antibodies that tag myelin proteins for 
macrophage destruction (figure 5). 
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Figure 5. Schematic view of the hypothesis of tolerance breakage via host cell protein incorporation into 
virus particles. The event starts with a neurotropic virus, such as HHV-6A, infecting oligodendrocytes. 
When it has budded off the virus capsid is wrapped in host cell membrane that contains host cell surface 
proteins, such as myelin proteins.  
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis was to investigate the role of HHV-6 in MS. More 
specifically the individual projects were aimed: 
 
1. To develop a robust method for HHV-6 titer assessment that is easy to interpret. 
 
2. To assess the potential of HHV-6A as an adjuvant, for triggering DC activation 
and T cell proliferation induction. 
 
3. To assess the frequency of active HHV-6 infections in MS patients compared to 
healthy controls, as seen by viral DNA in serum. 
 
4. To assess if the serological IgG antibody response against HHV-6 differs 
between MS patients and healthy controls, and furthermore if factors previously 
associated with MS susceptibility are associated with the antiviral IgG 
response. 
 
5. To assess if host genetics have an effect on the serological IgG antibody 
response against HHV-6. 
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3 MATERIALS AND METHODS 
3.1 EXPERIMENTAL STUDIES 
3.1.1 Cell culture and HHV-6A propagation 
In studies I and II cells of the T cell line HSB-2 were cultured and expanded in 
GlutaMAX containing RPMI 1640 medium supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin and 100 mg/ml streptomycin, referred to as complete 
RPMI. In paper II monocytes were isolated from buffy coats purchased from the 
Blood Transfusion Clinic at the Karolinska University Hospital. Briefly, monocytes 
were retrieved from the buffy coats using commercial kits and density gradient 
centrifugation on lymphoprep. For the generation of DC, purified monocytes were 
cultured for seven days in complete RPMI supplemented with 6.5 ng/ml of 
recombinant human IL-4 and 250 ng/ml of recombinant human granulocyte-
macrophage colony-stimulating factor (GM-CSF), fresh cytokines were added on day 
three. The yield of DC was determined by FACS and was typically >70% of CD14- 
CD1a+ live cells. 
 
HHV-6A strain GS [1] was propagated in the T-cell line HSB-2. When the cytopathic 
effect (CPE) was >50% the cell culture was centrifuged for 10 min at 300 g and the 
supernatant was harvested and stored in aliquots at -80°C. The 50% tissue culture 
infective dose (TCID50) was determined by ocular inspection of the cytopathic effect 
or a Q-PCR based read-out as described in paper I. For the infection experiments in 
paper I and II HSB-2 cells or DC were inoculated with 10
-1
-10
-6
 multiplicity of 
infection (MOI) for three hours before they were washed with incomplete RPMI 
medium and further cultured in complete RPMI. For the DC cultures the complete 
RPMI was supplemented with IL-4 and GM-CSF. As control for non-replicating 
infection, HHV-6A was inactivated with UV irradiation for 20 minutes. In paper I we 
saw by TCID50 that this treatment completely eliminates the replication capacity. 
After inoculation the infection was followed by longitudinal sampling for up to 
fourteen days and analyzed by Q-PCR targeting an immediate-early gene as described 
previously [244]. DNA was extracted using a commercial bead based kit that allowed 
for simultaneous extraction of up to 96 samples. The infected cells were also analyzed 
by immunofluorescence assay (IFA) by fixation onto glass slides with a 1:1 mixture 
of acetone and methanol at -20°C for 10 minutes, for blocking 5% goat serum and 3% 
bovine serum albumin in PBS was used, and the cells were stained with primary 
mouse MAbs specific to the late HHV-6 glycoprotein gp116/54/64 or early protein 
p41. The staining was visualized by an Alexa 633 conjugated F(ab’)2 fragment of 
goat anti-mouse IgG (Invitrogen). Staining with 4’,6-diamidino-2-phenylindole 
(DAPI) was used to visualize the cell nuclei. 
 
3.1.2 TCID50 set up 
For the TCID50 culture plate set up, cell suspensions of 40 µl containing 10
4
 HSB-2 
cells per well were seeded in round bottom 96-well culture plates. The cells were 
inoculated for three to four hours with 160 µl of five-fold dilutions of the HHV-6A 
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batch to be tested in six replicates per dilution. As negative controls for replication, 
mock and medium controls were included in triplicates. Mock was supernatant from 
uninfected HSB-2 cells. The culture plate was shaken every 20-30 minutes to enhance 
binding of virions to the cell surfaces. The cells were washed once before 50-70 µl of 
cell suspension were sampled from every well and stored in -80°C as zero days post 
infection (dpi) samples. The cells were allowed to sediment to the bottom of the wells 
in the washing step. After sampling the remaining cell suspensions were further 
incubated for seven days. At seven dpi, the zero dpi culture plate was thawed and 
subjected to DNA extraction, using the bead based kit, and Q-PCR for viral DNA 
measurement as described in section 3.1.2. 
 
3.1.3 Assessments of DC functions 
As positive control for maturation in paper II, DC were cultured with 100 ng/ml 
lipopolysaccharide (LPS) together with 500 U/ml IFN-γ. As negative control DC 
were inoculated with supernatant from uninfected HSB-2 cells, referred to as mock. 
 
3.1.3.1 Flow cytometry 
For flow cytometry in paper II, HHV-6A or mock inoculated DC were labeled with 
MAbs specific for the following markers: CD83, HLA-ABC, CD14, HLA-DR, 
CD40, CD86 and CD1a. To visualize and exclude dead cells from the analysis, the 
cells were also incubated with a live/dead marker. All labeling were performed on ice 
for 30 min in PBS containing 2% FCS, 5 mM EDTA and 0.01% sodium azide 
(NaN3). All flow cytometric analyses were performed with a CyAn flowcytometer 
and data was analyzed using the software FlowJo. For detailed information on the 
fluorochrome conjugation to each MAb see the materials and methods section in 
paper II enclosed in the end of this thesis. 
 
3.1.3.2 Cytokine measurements 
In paper II, supernatants from HHV-6A infected and control DC were examined for 
various cytokines important in inflammation and DC maturation. These included type 
I, II and III IFNs, IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70. Myxovirus resistance 
protein A (MxA) gene expression is only induced by type I and III IFNs, and hence 
represent a sensitive indicator of total levels of bioactive type I and III IFNs in 
samples [245, 246]. For analyses of the total level of bioactive type I and III IFNs we 
therefore used an MxA gene expression assay [247]. Briefly, levels of MxA mRNA 
were measured in cells of the lung cancer cell line A549, exposed to 100 µl 
supernatants collected from the DC cultures at 3 dpi. As standard we used therapeutic 
IFN-β. The A549 cells were exposed to the samples for 6.5 h followed by lysis in 
lysis buffer containing 50% Nucleic Acid Purification Lysis Solution in 1xPBS. The 
culture plate with cell lysate was stored in -80°C over night before mRNA was 
extracted. Thereafter, the mRNA was converted to cDNA using the High Capacity 
cDNA Transcription kit, prior to Q-PCR analysis with primers and probes targeting 
the MxA gene and 18S gene, where 18S was used as endogenous control of mRNA 
expression. To further determine the specific types of type I and III IFNs produced by 
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DC IFN-α, -β and -λ specific enzyme linked immunosorbent assays (ELISAs) were 
run using in-house methods for IFN- α and -λ and a commercial kit for IFN-β. For 
measurements of IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70 cytometric bead arrays 
(CBA) were used. 
 
3.1.3.3 Mixed lymphocyte reaction 
In paper II, the allostimulatory capacity of HHV-6A inoculated DC was evaluated by 
mixed lymphocyte reaction (MLR). Here 300–3000 live DC were co-cultured with 
10
5 
allogenic live T cells per well. Determination of cell numbers was performed 
using a phase contrast microscope after Trypan blue staining. CD3+ CD8+ and CD3+ 
CD4+ T cells were isolated from PBMC from buffy coats and purified as described 
above with the use of magnetic micro bead kits, according to manufacturer’s 
instructions. MLRs were incubated for a total of 96 hours. Eight hours before 
termination, 1 mCi [3H]-thymidine per well was added. The culture medium was 
complete RPMI supplemented with 50 mM 2-ME. After being pulsed with [3H]-
thymidine, the cells were harvested and the degree of [3H]-thymidine incorporation in 
proliferating T cells was analyzed. For 3H-thymidine incorporation and harvesting of 
cells the following material was used: 3H-thymidine, Tomtec harvesting machine, 
glass fiber filter, melt-on scintillation sheet, sample bags and 1450 Microbeta counter. 
To determine if HHV-6A infection of DC can skew the T helper cell profile into Th1 
or Th2 lineages CBA was performed on MLR supernatants targeting the cytokines 
IL-2, IL-4, IL-6, IL-10, TNF and IFN-γ. 
 
3.2 PATIENT STUDIES 
3.2.1 Patients and samples 
In paper III, stored plasma, serum and CSF samples taken as part of the clinical practice 
between the years 2002-2005 of patients with MS, Guillain-Barré syndrome (GBS), 
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and headache 
were used. The headache patients were used as control group. The MS patients were 
diagnosed using the McDonald criteria [6], the GBS patients using the Asbury criteria 
[248] and the CIDP patients using criteria from the American Academy of Neurology 
AIDS Task Force [249]. The MS patients were divided into three subgroups; treatment 
naïve, neutralizing antibody negative (NAb-) IFN-β treated and NAb+ IFN-β treated. 
The treatment naïve patients were newly diagnosed or showed signs of MS but had not 
yet fulfilled the full diagnosis criteria for MS. Therefore they are referred to as possible 
MS. 
 
In papers IV and V plasma samples were used from patients with MS, diagnosed using 
the updated McDonald criteria [7], and from healthy controls collected between the 
years 2005 and 2009 for research use. 
 
3.2.1.1 DNA extraction and nested PCR 
In paper III, DNA was extracted from plasma or serum and cerebrospinal fluid (CSF) 
from patients with possible MS, GBS and CIDP using a commercial kit. For 
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contamination control water was added to every fifth column. DNA was eluted in 
buffer and stored at -80°C. Subsequently, the eluates of all samples were screened for 
HHV-6 DNA using a nested PCR targeting the major capsid protein (MCP) gene as 
previously described [158]. Tests were considered valid if all water controls remained 
negative and if the viral laboratory strains U1102 and Z29, used as positive controls, 
were amplified. The MCP nested PCR sensitivity was 240 copies/ml, as determined by 
Q-PCR as previously described [244].  
 
3.2.1.2 Anti-HHV-6 IgG ELISA 
In papers IV and V, plasma anti-HHV-6 IgG antibody titers was assessed using a 
commercial ELISA Kit, with HHV-6B Z29 strain viral lysate as antigen, according to 
the manufacturers’ protocol. Briefly, all plasma samples (n=933) were run in at least 
duplicate wells. The titer results are given as optical density (OD) ratios, calculated by 
the OD value for the particular sample divided by two times the OD value for the 
negative control. The results were interpreted as suggested in the manufacturers’ 
protocol; OD ratios 0.75 were regarded as negative and OD ratios 1.00 as positive. 
Borderline samples (OD ratio 0.76-0.99, n=36) were excluded from the antibody status 
analysis but included when titers were analyzed. Samples with an OD ratio 0.75 were 
accepted only if the OD values had a coefficient of variance (CV) of less than 25%. 
The OD ratio of the positive controls on all plates had an inter-assay CV of 13%. 
 
In paper IV, plasma IgG responses against the early HHV-6 protein p41/38 and total 
IgG was also investigated in a subset of 67 patients and 67 healthy controls using 
commercial ELISA kits. All samples were run in duplicates and the experimental 
procedures were performed according to the kit specific protocols. For plasma IgG 
responses against p41/38 nOD values were obtained as for the anti-HHV-6 responses 
described above. For total IgG absolute quantification using a standard curve was 
performed. 
 
3.2.1.3 HLA typing and measurement of vitamin D level 
All samples in paper IV were genotyped typed for HLA-A and HLA-DRB1 using a 
commercial kit based on sequence-specific primers [250]. Genotypes for HLA-A and 
DR were unavailable for 17 and 23 patients, respectively. For these, HLA allele status 
was imputed using HLA*IMP01 [251] from high density genotypes generated in a 
genome-wide scan for MS susceptibility genes [12]. Levels of 25-hydroxyvitamin D2 
and D3 were measured in the plasma samples from all subjects in paper IV as 
previously described [252]. 
 
3.2.2 Genome-wide SNP typing and gene identification 
In paper V, genome-wide single nucleotide polymorphism (SNP) markers were 
genotyped as part of the International Multiple Sclerosis Genetic Consortium (IMSGC) 
Welcome Trust Case Control Consortium 2 (WTCCC2) MS Genome wide association 
study (GWAS) project using the Illumina Human660-Quad chip (Illumina, San Diego, 
CA, USA). Genotype calling and SNP markers were quality controlled as previously 
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described [12]. After the quality checks 483 232 markers remained, and of these 
472 716 markers were autosomal.  
 
Using the free and web based HapMap dsSNP tool accessible via the NCBI webpage 
(www.ncbi.nlm.nih.gov/projects/SNP/) genes within 50kb of each SNP were identified. 
As GWAS approaches yields very large amounts of data. Therefore this rather strict 
and well established threshold [11] was chosen, together with the decision to 
investigate only the nearest gene to each SNP, to limit the amount of candidate genes. 
If a gene laid within 50kb to the SNP together with a miscellaneous RNA (miscRNA), 
non-coding RNA or a pseudogene, the gene was listed. The rational for this was that 
the functional properties of miscRNAs are largely unknown and that non-coding RNAs 
and pseudogenes have lost the protein coding ability. 
 
3.3 STATISTICAL ANALYSES 
In paper I, Excel was used to calculate coefficients of variance (CV) when comparing 
the robustness different titration methods. In paper II Student’s t-test and one-way or 
two-way analysis of variance (ANOVA) with Bonferroni’s correction for multiple 
testing were applied using GraphPad. In paper III Fisher’s exact tests were performed 
using GraphPad. In paper IV linear regression analysis was performed using R version 
2.15.2. All samples (n=933) were analyzed together to assess relationships between 
anti-HHV-6 IgG nOD levels and the independent variables gender, affection status (MS 
patient or healthy control), smoking (never smoker or past/present smoker at sampling), 
age at sampling, vitamin D levels and HLA-A*02 and HLA-DRB1*15 carriership, and if 
statistically significant relationships existed between these variables. Multiple linear 
regression models were constructed for MS cases and controls together to determine if 
these variables interacted. For the MS case only model, the variables disease duration, 
treatment or no treatment and specific treatment types were included. Mann Whitney U 
tests were employed in STATISTICA when comparisons between two groups were 
made. For the MS patient group, Kruskal-Wallis test was performed in STATISTICA 
to determine if the nOD levels differed between the groups: treatment naïve (n=139), 
IFNβ (n=41) and Glatiramer acetate (n=11). 
 
In paper V logistic and linear regression analysis were performed to assess the effects 
of host genes, via GWAS SNP markers, on anti-HHV-6 IgG antibody status and 
levels. SNPs with high linkage disequilibrium to other SNPs in the analysis (r2<0.2) 
were first removed using PLINK 1.07 [19]. Subsequent analyses were performed on 
the MS patients and healthy control groups assembled, as no differences in anti-
HHV-6 IgG status or nOD levels was observed between the groups. Human leucocyte 
antigen HLA allele status were assessed by imputing the HLA alleles using 
HLA*IMP01 [21] from SNPs within the HLA region. HLA association was tested to 
both HHV-6 IgG status, using logistic regression, and to normalized HHV-6 levels 
using linear regression. Linear regression analysis for the GWAS analysis was 
performed in two ways; with all HLA alleles associated to HHV-6 levels included as 
covariate, respectively not included as covariates. Threshold for suggestive 
association was set to p<1*10
-4
 as in previous studies [11]. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
It is crucial to have control of the viral titer in experimental work with viruses. In paper 
I [253] we developed and validated an alternative read-out approach for the 50% tissue 
culture infectivity dose (TCID50) method [194] for HHV-6. The experimental 
procedure is described in more detail in paper I of this thesis. Briefly, we measured the 
increase in viral DNA load of every titration well in TCID50 culture plates using real 
time quantitative polymerase chain reaction (Q-PCR) after seven days of culture. The 
established method of ocular inspection for CPE is problematic at the borderline of 
infection in titration series’ as the cells enlarged due to infection tend to enlarge less 
with increased dilution of the virus (figure 6). IFA for TCID50 read-out [195] or for 
infectious units [196] is more distinct but the monitoring of individual cells is 
laborious. In addition, monitoring of individual cells for CPE or IFA implies a risk to 
misinterpret the cell’s positivity. 
  
 
Figure 6. Example of ocular inspection 
of HHV-6A (GS strain) infected HSB-2 
cells. Dilutions and positive (+) and 
negative (-) results in Q-PCR TCID50 
assessments are indicated. Undil: 
undiluted virus supernatant, 1:5; five 
times dilutions of virus supernatant 
etcetera. Photographs are taken using a 
lens for ten times enlargement. 
 
4.1.1 Assay development 
Primarily, the harvest time-point had to be determined. Longitudinal sampling of HHV-
6A inoculated cell cultures was performed for ten days. A plateau was seen at seven 
days post infection and was therefore chosen as the harvest time point. Secondly, the 
cut-point for viral DNA load increase that corresponded to true infection had to be set. 
To do this, cells from every well in three different TCID50 culture plates were subjected 
to IFA and the results were compared to the Q-PCR results of every culture well. The 
optimal cut-point was found at ten times increase in viral DNA load that corresponded 
to viral protein expression in 93% of the wells (figure 7). 
 
 
Figure 7. The optimal cut-point for 
infection was determined to a ten times 
increase in viral DNA load. At this point 
the correlation to viral protein expression 
was seen in 93% of the wells using IFA 
targeting the late viral protein 
gp116/54/64. Data shown are mean results 
(± SEM) for three TCID50 plates. 
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4.1.2 Assay validation 
Validation is a vital step when developing a new method. To validate our method we 
tested four different batches of HHV-6A (GS strain) multiple times and compared the 
titer results with the results from ocular inspection and IFA read outs of TCID50. In 
addition the use of IFA to determine the number of infectious units was used. For all 
batches the inter-assay CV values were measured. In this setting the inter-assay CV 
value gives a measure on the variability in the results when the assay is performed 
several times on the same virus batch. For our method the inter-assay CV was 73% 
whereas it was 66%, 25% and 77% for the ocular inspection read-out for TCID50, IFA 
read-out for TCID50 and infectious units respectively. These numbers are very high. It 
is not surprising however as they are all biological assays that depend on many factors 
such as the status of the cells, which in turn can be influenced by many factors such as 
the freeze thawing procedure. The efficacy of the infection is also a critical parameter, 
which in turn can depend on various factors such as the number of times the culture 
plate is shaken during incubation. Therefore, a more accurate measure on the 
robustness of a bioassay is the intra-assay CV value. In this setting the intra-assay CV 
value gives a figure of the robustness of the reading at an individual performance of the 
assay. To determine the intra-assay CV for our method we performed parallel duplicate 
extractions and Q-PCRs for three TCID50 culture plates to see to what extent the 
extraction and the Q-PCR influenced the results. For ocular inspection the intra-assay 
CV value was determined by twelve TCID50 culture plates read by two persons 
independent of each other to assess the extent of individual interpretations of infection. 
For the IFA read-out of TCID50 the intra-assay CV value was determined by duplicate 
staining and counting of cells from all wells from two different culture plates. Finally, 
for the infectious units approach the intra-assay CV value was determined by four 
parallel staining procedures of cells from one run. The intra-assay CV value for our 
method was 9% compared to 45%, 14% and 43% for the ocular inspection read-out of 
TCID50, the IFA read-out of TCID50 and infectious units approach respectively. 
Comparing the intra-assay CV values gives the conclusion that our method was more 
robust than the established methods.  
 
Some virologists use the HHV-6 DNA copy numbers in the virus batch as a rough 
estimate of the amount of infectious viral particles. We tested this idea and the viral 
DNA load did not correlate to the viral titers, when determined using any of the three 
established methods, nor when determined using our method. This indicates that 
measuring viral DNA in batch’s supernatants is insufficient to correctly assign the 
infectivity of a batch. Instead biological assays should be performed. 
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4.1.3 Conclusions 
Even though our novel read-out method proved most robust and is easier to interpret it 
has limitations. One is encountered when large amounts of free viral DNA is present. 
This DNA is unable to reach the cells’ interior and get replicated and furthermore 
yields a high signal in the sample before incubation. This can then mask the signal of 
the replicated DNA at seven days post inoculation giving the impression that a low 
amount of viral DNA has actually been replicated. This problem is typically seen in the 
culture plate wells that have been incubated with undiluted or five times diluted virus 
supernatants. A manifestation of this problem is when the viral DNA increase does not 
reach the cut-point in undiluted or five times diluted wells, but further down in the 
dilution series. In this scenario, the results of the wells further up in the dilution series 
can be excluded. 
 
To conclude, it is important that standardized and validated titration methods are 
harmonized within the HHV-6 field. This would facilitate comparisons between 
experimental studies performed in different labs. An assay that is easy to perform and 
interpret seems preferable, especially for people new in the HHV-6 field. 
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4.2 PAPER II 
The incorporation and molecular mimicry hypotheses are based on the idea that self-
proteins, such as myelin proteins, or viral proteins that mimic myelin proteins, become 
immunogenic when they are taken up by APCs together with HHV-6 virions. A first 
step to investigate this hypothesis is to assess if HHV-6 can mount an adjuvant effect 
on APCs in the absence of self-proteins. As DC are the most potent APCs that are 
central for activation of CD4+ and CD8+ T cells [102], this project was focused on 
HHV-6A exposure of DC [175]. 
 
4.2.1 HHV-6A cannot replicate in DC 
Previous studies report contradictory results on the replication capacity of HHV-6A in 
DC [143, 173]. Whereas Hirata et al. [143] suggests that DC can support HHV-6A 
(U1102 strain) replication, Smith et al. [173] suggests that DC cannot support HHV-6A 
(GS strain). Therefore we wanted to further investigate this notion. We did not see any 
increase in neither viral protein nor DNA (figure 8) supporting the report by Smith et 
al. The discordant results might be due to the different viral strains used or different 
passages of the virus, as the characteristics of cells and viruses are altered upon in vitro 
cultivation [151, 156]. To control for degraded viral batches or suboptimal infection 
procedures susceptible cells were infected in parallel with DC using the same virus 
supernatants. Both we and Smith et al. did then see infection in the susceptible cells 
suggesting that lack of viral replication seen in DC was not due to problems with the 
virus stock or infection procedure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. HHV-6A infection for 6 to 7 days of DC (A) or HSB-2 cells (B), as positive control. As 
negative control DC were inoculated for 6 days with mock, supernatant from uninfected HSB-2 cells (C). 
The cells were stained with an anti-HHV-6 MAb (red) specific for the late viral protein gp116/54/64 and 
with DAPI (blue). Scale bars are 50µm. Replication was also assessed by Q-PCR analysis of intracellular 
(D) and extracellular (E) viral DNA after HHV-6A inoculation of DC (open circles) and HSB-2 cells 
(filled squares). Inoc: inoculum, dpi: days post infection, hpi: hours post infection. Data are means (± 
SEM) for three donors. 
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4.2.2 HLA-ABC up-regulation via IFN-α 
To assess if DC are matured upon HHV-6A inoculation we analyzed the supernatants 
for type I IFN, and the cells for surface expression of various activation markers. We 
saw that exposure to HHV-6A induced up-regulation of HLA-ABC, HLA-DR and 
CD86 on the DC cell surface (figure 9A). Furthermore, our data show that exogenously 
added IFN-α can mediate up-regulation of HLA-ABC (figure 9B) as previously 
reported [77], and that DC can produce IFN-α upon HHV-6A exposure (figure 9C). 
The link between HHV-6A induced IFN-α secretion and HLA-ABC surface expression 
is further supported by our finding that addition of an anti-IFN-α antibody in the culture 
medium prevent the up-regulation of HLA-ABC (figure 9D). 
 
Interestingly, when the virus inoculum had been UV-treated prior to infection, DC 
exhibited a trend of reduced IFN-α response, compared to when the virus inoculum had 
not been UV-treated (figure 9B). This suggests that the UV-treatment might destroy 
important motifs of the virion that can induce IFN-α secretion, such as TLR ligands. 
Another option is that HHV-6A do replicate at low levels, under the detection limit of 
the IFA and Q-PCR assays used, resulting in an elevated number of ligands accessible 
for host cell receptors such as TLRs. As discussed in section 1.1.4 type I IFNs, such as 
IFN-α, are central molecules in antiviral immunity and important to measure when 
assessing the effect of a virus on DC functions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. DC respond to HHV-6A infection at 3 days post infection (dpi) with increased surface 
expression of HLA-ABC, HLA-DR and CD86 compared to mock, as seen with flow cytometry (A). DC 
produce IFN-α at 3 dpi upon HHV-6A as seen with ELISA (B). HLA-ABC surface expression is up-
regulated at 1 dpi upon HHV-6A exposure and also upon addition of exogenous IFN-α for 24h (C). In 
another experiment DC were inoculated with HHV-6A for three hours before they were washed and 
cultured in medium in the presence or absence of a polyclonal anti-IFN-α antibody in the culture medium. 
At 3 dpi the cells were harvested and analyzed for surface expression of HLA-ABC, HLA-DR and CD86. 
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Figure 9 (continued). Representative histograms from live CD1a+ DC from one of seven donors is 
shown in panel A. Data is shown as mean results (± SEM) for at least six donors and analyzed using 
ANOVA with Bonferroni’s multiple comparison test for panel B and for four donors and analyzed using 
Student’s t-test for panels C and D. *p<0.05, **p<0.01, ***p<0.001. DC where inoculated with HHV-6A 
supernatants at 0.01 MOI for all panels. 
 
Previous studies assessing cell surface HLA-ABC expression on DC after HHV-6A 
exposure report conflicting results. Whereas Hirata et al. [143] reported a down-
regulation Smith et al. [173] reported an unaltered HLA class I expression. This 
indicates that down-regulation is dependent on productive viral replication given that 
Hirata et al. saw viral replication, whereas we and Smith et al. did not, as discussed 
above. 
 
4.2.3 Modulation of inflammatory cytokine secretion 
Inoculation with HHV-6A reduced the capacity of DC to secrete IL-8 compared to 
mock (figure 10A). When the virus had been UV-treated prior to inoculation this effect 
was lost (figure 10B), again suggesting that HHV-6A might replicate at low levels and 
that the reduced secretion of IL-8 is dependent on replication capable virus. If HHV-6A 
has an ability to attenuate the IL-8 secretion in vivo then attraction of neutrophils might 
be hampered, as IL-8 can induce trafficking of neutrophils across vascular walls [254]. 
Since neutrophils are important cells of the innate immune system [255], impaired IL-8 
secretion might constitute a potential immune evasion strategy by the virus. However, 
this effect seems to be overridden when other inflammatory stimuli are present, as 
addition of LPS and IFN-γ in the culture medium led to slightly elevated IL-8 secretion 
by HHV-6A exposed DC compared to mock, although not significantly (figure 10C).  
 
HHV-6A exposure also led to augmented TNF and IL-12p70 levels (figure 10D and 
10E). This is in contrast to two studies by Smith et al. which suggest that pre-exposure 
with HHV-6A suppresses LPS and IFN-γ induced IL-12p70 secretion by DC [173] and 
also by macrophages [172]. This divergence might be due to different procedures used 
for virus propagation. We used the virus supernatants directly after centrifugation of the 
virus cultures, whereas Smith et al. ultracentrifuged their supernatants prior to 
inoculation. In their discussion they argue, that ultracentrifugation should be performed 
in order to remove cytokines from the supernatant that might affect the IL-12p70 
secretion. To investigate this notion we tested our virus inoculum and mock with CBA 
targeting IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNF and IFN-γ, and the MxA 
bioassay targeting type I/III IFN. All cytokines were present at negligible levels close 
to the lower detection limits of the assays and no differences were detected between 
virus inoculum and mock (data not shown). Therefore, we conclude that the differences 
are likely not due to the presence of other cytokines. Another option is that cell debris 
from dead cells, used for propagation, is present in the crude supernatant and are 
removed upon ultracentrifugation. One could argue that ultracentrifuged virus is 
cleaner than crude virus supernatants but the question is what preparation that best 
mimics the in vivo situation, clean virions or a virion and cell debris mixture? Anyhow, 
the idea that cell debris affects the results could be tested by redoing the experiments 
with ultracentrifuged and non-ultracentrifuged virus supernatants in parallel and also 
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treat DC with lysed uninfected cells to assess if the effect is virus specific, cell debris 
specific or a combination of both. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Replication competent HHV-6A (0.01 MOI) (grey or filled circles) reduced IL-8 secretion by 
immature DC at 3dpi compared to mock (black) (A) and also compared to UV inactivated HHV-6A (0.01 
MOI) (filled squares) (B). In the presence of LPS and IFN-γ HHV-6A (0.01 MOI) (open triangles) 
slightly accentuated the secretion of IL-8 compared to medium only (filled triangles) (C), and also of 
TNF (D) and IL-12p70 (E). In panels A and B, DC where inoculated with HHV-6A in non-UV or in UV-
inactivated form or with mock as negative control for three hours before they were washed and cultured 
in complete RPMI. In panels C, D and E, DC were cultured in complete RPMI supplemented with LPS 
and IFN-γ after the washing step. The cytokines were measured using CBA and data is shown as mean 
results (± SEM) for four donors and analyzed using two-way ANOVA for all panels except panel A were 
data is shown as mean results (± SEM) for at least seven donors and analyzed using Student’s t-test. 
*p<0.05. 
 
4.2.4 Suppressed allostimulatory capacity 
Even though DC seem to be at least partly activated upon HHV-6A exposure, 
inoculation by the virus suppressed the capacity of DC to stimulate allogenic CD4+ T 
cell proliferation, as seen with MLRs (figure 11A and 11B). Interestingly this effect 
was further increased when the virus had been UV-treated prior to inoculation (figure 
6B), indicating that the suppressed allostimulatory effect is independent of virus 
replication. These data are supporting two previous studies [144, 173] where DC were 
infected in vitro, and furthermore analogous with the data from an in vivo study where 
the leucocyte counts were significantly decreased in children with primary HHV-6 
infection compared to in non-infected children [256]. Previous studies suggest that 
HHV-6A and HHV-6B can induce accumulation of p53 and that at least HHV-6B can 
protect the infected cell from apoptosis [257], indicating that an active replication might 
rescue the cells from apoptosis. However, inoculation with UV-inactivated virus in 
paper II of this thesis induced cell death to a similar extent as did inoculation with non-
UV-inactivated virus at three dpi (figure 11C) suggesting that HHV-6A replication did 
not rescue the cells from apoptosis in this setting.  
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CBA targeting the Th1 associated cytokines IL-2 and IFN-γ and the Th2 associated 
cytokines IL-4, IL-6 and IL-10 suggested that a skewing towards a Th2 pathway was 
induced upon HHV-6A exposure (figure 11D). However, the effect was quite modest 
and a review of the literature suggests that this is usually the case upon HHV-6A 
infection. In vitro infection of PBMC induced both IFN-γ and IL-10 [258] and in vivo 
cytokine measurements in the serum of primary HHV-6 infected children revealed that 
the Th1/TH2 balance seems to tipped in neither direction [259].  
 
Figure 11. HHV-6A inoculation of DC suppresses their capacity to stimulate allogenic CD4+ T cell 
proliferation in mixed lymphocyte reactions (A and B). HHV-6A infection induces DC cell death (C) and 
skewing towards a Th2 pathway upon co-culture with allogenic T cells (D). In panel A, representative 
results for one of four donors are shown and data points are mean results (± SEM) of counts per minute 
(cpm) for triplicate wells. In panel B cpm mean results (± SEM) of at least four DC donors expressed as 
percentage in cpm responses compared to mock stimulated DC are shown. In panel C the bars 
represent the mean results (± SEM) of two to five donors. In panel D the results of CBA targeting IL-2, 
IL-4, IL-6, IL-10 and IFN-γ of supernatants from DC from three donors exposed to HHV-6A for three 
days prior to co-culture with allogenic T cells are shown. Data points represent the cytokine levels 
from HHV-6A (6A) and mock (M) exposed DC, normalized to mock. The IL-2 and IFN-γ constitute 
the Th1 group and IL-4, IL-6 and IL-10 the Th2 group. Median values for each group are marked with 
solid black lines. The data were analyzed using paired t-tests for panels B and D and unpaired t-test for 
panel C. *p<0.05, **p<0.01, ***p<0.001, ns: not signicifant.  
 
 
4.2.5 Summary and conclusions 
Taken together the results of paper II demonstrate that HHV-6A cannot replicate 
productively in DC. The cells got activated upon inoculation as seen with up-regulation 
of HLA-ABC via autocrine IFN-α signaling, and up-regulation of HLA-DR and CD86. 
HHV-6A suppressed the secretion of IL-8 in immature DC but this effect was 
overridden when other stimuli such as LPS and IFN-γ were present. The presence of 
LPS and IFN-γ also led to augmented secretion of TNF-α and IL-12p70 in HHV-6A 
inoculated DC. Inoculation of UV-inactivated virus induced somewhat less IFN-α 
secretion and a smaller augmenting effect on IL-8 secretion suggesting that HHV-6A 
might be able to replicate at low levels that were not detected by IFA or Q-PCR. A 
complementary approach could have been to assess replication by reverse transcriptase 
(RT)-PCR targeting a number of HHV-6A genes transcribed at different stages of 
infection. This might give information on whether a subset of genes are transcribed that 
could influence functional mechanisms of the cell. 
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So, do the data of paper II favor the incorporation hypothesis? DC get partly mature 
and partly activated but the vital action of DC in antiviral immunity, to induce T cell 
proliferation, is impaired (figure 12). One could argue that a potential bias in the MLR 
experiments is that HHV-6A induced an increased and titer dependent cell death of DC 
compared to mock at 3 dpi, which is the harvest time-point (figure 11C). In the MLR 
experiments the DC are further cultured for four additional days in the presence of 
allogenic T cells before the MLRs are harvested. Even though the identical number of 
live DC were added for the different stimulations in the initiation of the MLRs, the 
HHV-6A infected DC might die to a larger extent than mock inoculated DC over the 
course of the MLRs, resulting in an impaired potential for the T cells to receive 
proliferative stimuli. Hence, the assumed HHV-6A induced “anti-allostimulatory 
effect” might very well just be a result of dying DC in the MLR cultures. However, the 
single previous study on allostimulation by HHV-6A infected DC by Smith et al. also 
report a suppressive effect of HHV-6A and they harvested their DC after 17 hours 
[173]. Together our report and the Smith report suggest that HHV-6A do not 
constitutes an adjuvant effect, at least not in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Schematic picture of the findings in paper II. Red crosses and up-pointing arrows represent 
inhibition and up-regulation respectively. 
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4.3 PAPER III 
Many studies suggest an association between HHV-6 and MS. However, to date the 
total cumulative body of indications for a causal relationship provides only just that, an 
indication that HHV-6 might have a role in the cause or course of MS. One way to 
prove an HHV-6 etiology in MS would be if a clinical improvement could be observed 
after antiviral treatment targeting HHV-6. Patients who, during the course of disease 
have shown evidence of active viral infection or possibly a shift in anti-HHV-6 
responses would be eligible for such a trial. To screen for these patients a robust, rapid 
and cost-effective method is required. 
 
In paper III [260] we analyzed plasma and cerebrospinal fluid (CSF) using nested PCR. 
We found HHV-6 DNA in plasma and CSF in two and one of 27 possible MS patients 
respectively. Even though no viral DNA was found in any of the 33 headache patient 
controls the differences were not statistically significant. Hence, screening of cross-
sectional samples for viral DNA at one time-point only does not seem to be the optimal 
approach to identify patients with active HHV-6 replication. Given the short periods of 
time when HHV-6 DNA is detectable longitudinal sampling would be preferred. In 
addition, serological screening for anti-HHV-6 IgM antibodies might be an easier 
measure of active replication.  
 
Plasma and serum was used for analysis as it has the advantage of being easily 
accessible for sampling, but it might not reflect the viral status in the brain. CSF is a 
more accurate compartment when studying the brain [261] but is much more 
inconvenient to sample, for the clinician and of course even more for the patient. The 
aim of analyzing plasma and CSF samples in combination was to assess their 
concordance for HHV-6 DNA. None of the patient was positive in both plasma and 
CSF suggesting that local reactivations can occur. Nested PCR was chosen since it is 
cost-effective and rapid. However, it implies a risk for false positive results, so for a 
robust analysis it can be combined with sequencing of the PCR product to determine 
that a HHV-6 sequence has actually been amplified. Sequencing was not prioritized in 
paper III due to the low number of positive samples. Another drawback with nested 
PCR on plasma or serum samples is the risk of detecting viral DNA that has leaked out 
from lysed PBMCs. However, sensitivity is more important in screening approaches. 
Subsequently additional assays with higher specificity can be applied such as Q-PCR 
could have been applied if a higher frequency of HHV-6 DNA positive samples had 
been detected. However, given the negative results of paper III we did not find this 
procedure necessary. To conclude, given the low frequency of positive findings in this 
study screening for HHV-6 DNA in a cross-sectional setup does not seem to be an 
appropriate approach to identify MS patients where the virus might influence the 
disease. 
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4.4 PAPER IV 
Genetic as well as environmental factors have been suggested to contribute to MS 
susceptibility. The strongest genetic risk allele for MS disease onset is HLA-DRB1*15 
[11, 12, 19], and HLA-A*02 is a protective allele [21, 22]. Suggested environmental 
factors include low vitamin D levels [262], smoking [43] and various infections agents 
[263] such as HHV-6. Female sex is also a risk factor as more women than men are 
affected. Most studies have been focused on either genetics or environment, and many 
studies have investigated one risk factor only. However, interactions between these 
may occur. Therefore, focusing on HHV-6 biology, the aim of paper IV was to 
characterize the anti-HHV-6 IgG response in MS patients and healthy controls, and to 
assess if factors that can influence MS susceptibility can also affect the serological 
response against HHV-6. 
 
The serum anti-HHV-6 IgG seroprevalence was 90%. No difference between MS 
patients and healthy controls was observed. This topic is controversial as different 
studies where whole virion lysate was used as antigen as some see an increased anti-
HHV-6 IgG antibody titers in MS patients compared to controls [264-266], whereas 
others do not [200, 207, 267, 268]. Our study is the largest and together with the other 
negative studies it sets the controversy in favor for the notion that an increased IgG 
response against whole HHV-6 virions is not regularly seen in MS. However, it does 
not rule out the role for HHV-6 in MS. As the serological response against different 
HHV-6 proteins can differ [202] it is possible that a low response against a certain 
protein can be compensated by a higher response against another. Therefore 
investigation of individual proteins might be more informative. The central tissues in 
the pathophysiology in MS are within the CNS. However, sampling of serum or plasma 
is considerably more convenient than CSF and therefore investigations of relevant 
markers in the periphery of HHV-6 infection relevant in MS are warranting. 
 
No difference in anti-p41 IgG levels was seen between MS patients and controls. As for 
antibody responses against HHV-6 lysate different studies report contradictory results 
[191, 202, 269]. The discrepancy might explained by the different assays used that 
applied antigens purified by different methods. Interestingly, serological in CSF 
responses against HHV-6A have been shown to be more abundant and antibodies of 
higher titers compared to HHV-6B suggesting a predominant role for HHV-6A in the 
CNS in MS disease [201]. A more detailed investigation assessing the HHV-6A or 6B 
species specific responses in the relatively large material that constitute this study 
would be very interesting. However, for a plausible performance it would require a 
convenient assay such as ELISA. 
 
IgG levels might be regarded as a sign of history of infection. An increased frequency 
of reactivations of HHV-6 has been seen in RRMS during relapses [15, 16]. As 
incerased serum IgG titer against HHV-6 have been shown to positively associates with 
relapse risk in MS [212] an incerased frequency of reactivations might influence the 
MS disease and furthermore be reflected by an accumulating IgG levels in serum. 
However, we did not see this. Instead, the level of antiviral IgG antibodies against a 
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common virus such as HHV-6 might be interpreted as a reflection of a general activity 
that is influenced by various factors. Such factors include HLA types, serum vitamin D 
levels tobacco smoking and gender. As the anti-HHV-6 IgG response did not differ 
between MS patients and controls they could be grouped together in the analyses.  
 
Interestingly, carriership of the MS protective allele HLA-A*02 and tobacco smoking 
was associated with lower anti-HHV-6 IgG levels (p<0.001 and p<0.02 respectively), 
whereas females sex was associated with higher levels (p<0.02) (figure 13). No 
influence was seen for carriership of the MS risk allele HLA-DRB1*15 or for serum 
vitamin D levels. It is well known that CD8+ cytotoxic T cell mediated immunity is 
very important in viral infections. With the interaction to HLA class I molecules on 
infected cells it is not surprising that we see an association to a HLA class I genes and 
not to a HLA class II gene. One mechanism underlying the protective effect of HLA-
A*02 against high levels of anti HHV-6 IgG antibodies might be its ability to present 
peptides without loading via the transporter associated with antigen processing (TAP) 
complex [270]. Both EBV and CMV encode for proteins that can block the TAP-
mediated peptide loading on major histocompatibility complex (MHC) class I [271, 
272]. If HHV-6 has a protein with a similar function then a lower people carrying 
HLA-A*02 might handle the primary infection and/or reactivations more efficiently. 
This could serve as a mechanistic explanation if increased anti-HHV-6 IgG levels can 
be utilized as a reflection of the history of the magnitude or frequency of an infection or 
reactivation. Hence, whereas HLA-A*02 might protect against HHV-6 mediated MS 
onset, providing a possible explanation for its protective effect against MS, HLA-
DRB1*15 might present myelin peptides efficiently and thereby contribute to disease.  
 
 
Figure 13. Anti-HHV-6 IgG antibody response in MS patients (MS) and in healthy controls (HC), 
divided by HLA-A*02 carriership (A), gender (B) and smoking habits (C). Each dot represents one study 
participant. Median titers are marked with red lines. P-values are calculated using Mann Whitney U Test. 
 
Female gender was associated with higher anti- HHV-6 IgG levels, possibly reflecting 
a more active serological immunity compared to males. Furthermore, this study 
revealed that smoking lowered the antibody response against HHV-6, which could be 
explained by a decrease in general serum IgG by tobacco smoking [273]. 
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In conclusion, although no difference was seen in IgG response against HHV-6 
between MS patients and controls, the serology measured was associated with factors 
previously associated with MS susceptibility. This indicates that an IgG response 
against a common virus like HHV-6 might be regulated by similar factors that also 
regulate susceptibility to autoimmune diseases like MS.  
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4.5 PAPER V 
As HHV-6 is a ubiquitous virus that can establish lifelong latency in the host, factors 
like host genetics might play important roles in regulating anti-HHV-6 immune 
responses, which could have consequences for the establishment of latent infection and 
reactivation. The aim of this study was to investigate the influence of host genetics on 
the serological response against HHV-6 in the MS patients and healthy controls 
measured in project IV. 
 
As no difference in anti-HHV-6 IgG status or levels was detected the patients and 
healthy controls were assembled in the analyses. All study subjects had been genotyped 
with nearly 500 000 SNP markers over the entire genome. The allele of each SNP was 
analyzed for association to antibody status or levels using logistic or linear regression 
analysis. Given the continuous and even distribution of anti-HHV-6 IgG levels seen in 
the study population (figure 13, paper IV) the cut-point level seemed somewhat 
arbitrary. Therefore, the results of the linear regression analysis might be more robust 
and reliable. Initially, the SNPs within the HLA region were used to impute the HLA 
alleles and investigate associations to antibody status or levels. No allele was associated 
to status but the association between HLA-A*02 and lower antibody levels (p=0.004, 
β=-0.123) found in paper IV was found also using SNP imputation only instead of 
classical HLA typing as was primarily used in paper IV. A discussion on possible 
mechanisms for this association is given in section 4.4. HLA-DQA1*05 was also 
associated to serological response against HHV-6 but to higher antibody levels 
(p=0.018, β=0.105). Whereas the biological characteristics of the HLA-A*02 molecule 
is well known less is known about the HLA-DQA1*05 molecule. Upon vaccination 
against Measles virus HLA-DQA1*05 carriers respond with lower serum IgG antibody 
levels [274]. One possible and straight forward explanation for the association between 
higher levels of antibody against HHV-6 in HLA-DQA1*05 carriers is that the HLA-
DQA1*05 molecule have high affinity for certain HHV-6 peptides and thereby can 
facilitate efficient peptide presentation by B cells and thus higher antibody production. 
However, the binding of HHV-6 peptides to HLA-DQA1*05 molecules remains to be 
experimentally investigated. 
 
In further linear (figure 14A) and logistic regression (figure 14B) analyses the HLA 
region was included as a covariate. Interestingly, the linear regression analysis revealed 
suggestive association (p<1*10
4
) to a SNP (rs17162994) within 50 kilo base pairs (kb) 
from the TRBV5-1 (T cell receptor beta variable 5-1) gene. Clearly, the TCR is a central 
molecule in both cellular and humoral immunity and given the abundant presence of αβ 
T cells over γδ T cells in circulation, the αβ T cells seem to be the lineage that is most 
linked to B cell help and in turn to antibody production. Therefore, an association 
between antibody responses against a common virus such as HHV-6, and a locus in the 
TCR β chain is not unexpected. The αβTCR is important also during T cell 
development. Assuming that the magnitude of primary infection and the magnitude 
and/or frequency of reactivations of HHV-6 are reflected by the antiviral IgG antibody 
response, an efficient cellular immune response by CTLs, which can control the 
infection, might be reflected in lower serum anti-HHV-6 IgG levels. The TCR has a 
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central role also in cellular immunity and therefore, the suggestive association seen 
between anti-HHV-6 IgG levels and an allele of the TRBV5-1 gene might constitute a 
negative image of the antiviral cellular immunity. 
 
Three additional genes with potential impact on Th cell development and Th1 or Th2 
skewing were identified with suggestive association to anti-HHV-6 IgG levels: CMIP 
(rs2966097), RUNX1 (rs2186290) and MAML3 (rs6835277), and one with suggestive 
association to anti-HHV-6 IgG status: KSR2 (rs10850917, rs7295136 and rs17619337). 
Together, the findings suggest that the magnitude of anti-HHV-6 IgG antibody 
secretion is affected by host genes with potent impact for T cell development and Th1 
or Th2 skewing. As the association to the HLA-DQA1*05 allele, neither these are 
unexpected finding. As the readout of the viral assay is the antiviral serological 
response it is likely that associations are seen to genes with impact on antiviral 
immunity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Manhattan plot with p-values from the linear (A) and logistic (B) regression analyses of 
GWAS markers, investigating association to anti-HHV-6 IgG nOD levels or status, respectively. HLA-
A*02 and HLA-DQA1*05 were included as covariate in the linear regression analysis. Each dot represents 
the p-value of one marker, the lower horizontal line indicates the threshold for suggestive association 
p=10
-4
 and the upper horizontal line p=10
-8
, the threshold for GWAS association is p=5*10
-8
. 
 
 
To conclude, in this study we report for the first time results of a GWAS approach in 
HHV-6 infection. Furthermore we report a novel HLA allele with suggestive 
association to higher anti-HHV-6 IgG levels, HLA-DQA1*05. Furthermore, this study 
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provides several non-HLA genes with potential impact on serological immunity against 
HHV-6. Interestingly, a gene coding for a variable part of the TCR β chain was 
identified together with several genes with importance for skewing the Th cell 
population into Th1 or Th2 lineages. To investigate functional SNPs within the same 
haplotype blocks as the SNPs identified re-sequencing of the region of interest could be 
used. Even though none of the non-HLA markers reached the GWAS significance 
threshold further investigations in a larger material are warranting. 
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5 CONCLUDING REMARKS 
To summarize the biological findings and methodological advances in this thesis: 
1. Q-PCR read-out of TCID50 is more robust than established methods. As 
different approaches yield different results on the same virus batch, the titration 
methods used within the HHV-6 field should be harmonized. 
2. HHV-6A cannot replicate productively in DC but induce partial activation as 
seen by IFN-α mediated up-regulation of HLA-ABC, and up-regulation of 
HLA-DR and CD86. HHV-6A suppresses the IL-8 secretion and capacity to 
stimulate T cells, but augments IL-12p70 and TNF secretion. 
3. Active replication of HHV-6 is not seen more often in MS patients than in 
controls, or at least, is difficult to detect in cross sectional samples. 
4. The presence and levels of anti-HHV-6 IgG antibodies does not differ between 
MS patients and healthy controls, and the seroprevalence is 90%. However, 
anti-HHV-6 IgG antibody levels are associated with HLA-A*02 carriership, 
smoking and gender, factors all linked to MS susceptibility. 
5. Anti-HHV-6 IgG levels are significantly associated with HLA-DQA1*05 
carriership. Furthermore anti-HHV-6 IgG status and levels show suggestive 
association to a locus in the gene encoding the TCR beta variable chain and to 
genes with importance for steering the Th cell population into Th1 or Th2 
lineages. 
 
As exemplified from different angles throughout this thesis the support for an immune 
component in MS is overwhelmingly strong. The action of our immune system is 
specific and requires an activation signal. As discussed above the host cell protein 
incorporation hypothesis for tolerance breakage and MS induction, which was the 
starting point of this thesis, fulfills these two criteria. However, it implies other 
problems. 
 
Both HHV-6A and HHV-6B have the capacity to infect oligodendrocytes, but the 
release of free virions is not commonly seen [150, 275, 276]. However, HHV-6A can 
induce vigorous apoptosis of a human oligodendrocyte cell line in vitro [154]. 
Evidences for a productive infection of oligodendrocytes with the release of cell free 
virions, is a vital step in the incorporation theory that needs to be clarified. 
Furthermore, these virions should be shown to contain myelin proteins. Both HHV-
6A and HHV-6B [150, 277], can induce cell-to-cell fusion which seems to be a 
mechanism for viral spread [146, 183], therefore the requirement of cell free virions 
for this hypothesis might be somewhat problematic to meet. The notion of limited 
amounts of cell free virions in HHV-6 cultures is also supported by my personal lab 
experiences on virus propagation. Even though optimal cell lines were used, harvest 
of cell free supernatant yielded an infectious batch in around 10% of cases. In 
addition, given the numerous immune evasion strategies employed by HHV-6 it 
seems unlikely that the HHV-6 virion would constitute a potent adjuvant. In paper II 
we showed that HHV-6A exposed DC have hampered capacity to activate allogenic T 
cells. This effect was replication independent as UV treated virus had the same effect. 
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So what does this mean, that autoimmunity is not the major driving force in MS? An 
interesting discrepancy between EAE models and MS is that whereas myelin specific T 
cells are found at higher frequencies in EAE animals compared to healthy animals, this 
is not seen in MS, compared to controls, even though myelin-specific T cells from MS 
patients are of a more pro-inflammatory character [18]. It could be argued that feed-
back mechanisms are at play in MS disease shutting down the immune reaction after an 
attack, which results in the unaltered frequencies. But it seems likely that if autoreactive 
immune attacks are the primary event in MS then the frequencies of myelin specific 
cells should be increased, given that myelin proteins are major targets. 
 
An alternative explanation to a primary autoimmune attack, and to the host cell 
protein incorporation hypothesis, is that the mechanism of action in the onset of MS 
pathogenesis is provided by the HHV-6 infection itself. However, it does not seem to 
be as clear-cut as the host cell protein incorporation hypothesis assumes. Instead of 
buddying of myelin protein containing virions, the onset of events is more likely to start 
with a lytic infection of oligodendrocytes leading to the upregulation of MMPs, which 
enhance influx of leucocytes. Even though the influx of leucocytes into the CNS is 
dependent also on the interaction between the activation induced molecule VLA-4 on 
leucocytes and VCAM-1 on the capillary endothelial cells, it seems likely that virus 
specific leucocytes can infiltrate CNS tissues to screen the tissue for local reactivations 
as neurotropic viruses such as HHV-6 can reactivate locally in the CNS [260, 278]. 
Therefore, the criteria of peripheral activation might not be that strict. 
 
To conclude, the discussion on virus induced MS onset reveals that a comprehensive 
theory of a mechanism for MS onset is very difficult to pose with pitfalls all over. 
Instead of designing in vitro experiments to prove a specific hypothesis, my position is 
that research on a virus etiology of MS should be performed closer to the patients. As 
discussed in section 1.3.4 a randomized, placebo-controlled and double blinded clinical 
trial with an efficient anti-HHV-6 drug should be conducted on MS patients in the 
search for a proof of principle. Firstly, the prodrug for ganciclovir VGCV has proven to 
be safe in the treatment on CFS patients [227] and ganciclovir have well documented 
efficacy against HHV-6 [224]. However, the specific efficacy of VGCV against HHV-
6 should be investigated further before starting a trial. Secondly, CIS patients may be a 
good study group as HHV-6 has a suggested role primarily in early events of MS. 
Thirdly, if HHV-6 is important for the pathogenesis in only a subset of MS patients, 
those with a serological response in the CNS, suggesting a local CNS reactivation, are 
probably the ones that would benefit from antiviral treatment. And finally, a reliable 
virological method should be developed and used to assess the effect on the virus by 
the treatment. A marker of CNS infection that can be detected in peripheral blood 
would be desirable as blood is much more convenient to sample than CSF. If VGVC 
treatment of CIS patients reduces the HHV-6 load and induces a clinical 
improvement, then the time has come to investigate mechanisms that may underlie a 
HHV-6 induced pathogenesis of MS. 
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